

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 April 2005 (28.04.2005)

PCT

(10) International Publication Number
WO 2005/037303 A1

(51) International Patent Classification⁷: **A61K 38/17**,
C07K 14/47

(21) International Application Number:
PCT/US2004/030986

(22) International Filing Date:
22 September 2004 (22.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/505,264 22 September 2003 (22.09.2003) US

(71) Applicant (for all designated States except US): **BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS** [US/US]; The Henry Administration Building, 506 South Wright Street, Suite 349, Urbana, IL 61801 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **PRABHAKAR, Bel-lur, S.** [US/US]; 511 St John's Court, Oak Brook, IL 60523 (US).

(74) Agent: **MARTIN, Alice, O.**; Barnes & Thornburg LLP, P.O. Box 2786, Chicago, IL 60606-2786 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND COMPOSITIONS OF IG20 AND DENN-SV SPLICE VARIANTS



(57) Abstract: Methods and compositions relating to IG20 expression, splice variants of IG20, effects of endogenous DENN-SV function with respect to processes regulating cell proliferation, cell survival and cell death are disclosed.

WO 2005/037303 A1

METHODS AND COMPOSITIONS OF IG20 AND DENN-SV SPLICE VARIANTS

INVENTOR: Bellur S. Prabhakar

BACKGROUND

[0001] Methods and composition of IG20 and DENN-SV splice variants are useful for making cells more susceptible or resistant to apoptosis and/or induced cell death.

[0002] Eukaryotes have evolved the process of alternative mRNA splicing for generating multiple protein isoforms from the same gene. It is a highly regulated process that ensures removal of nucleotides at specific locations without disrupting the open reading frame. Alternative mRNA splicing could remove either a whole exon or part of an exon resulting in different transcripts capable of encoding related, but distinct, proteins. Since the completion of the human genome sequencing, it has become apparent that the biological complexity seen in humans, relative to other lower species, is most likely due to a higher degree of alternative splicing in human genes. *IG20* is one such gene that undergoes alternative mRNA splicing resulting in the production of multiple proteins.

[0003] cDNAs, including that encoding IG20 are differentially expressed in human insulinomas. cDNAs encoding MADD/DENN (MAP Kinase-Activating Death Domain-containing protein/Differentially Expressed in Normal and Neoplastic cells), KIAA0368 and DENN-SV (a short variant of DENN-SV) have near identical sequences, yet different actions.

[0004] Over-expression of MADD can enhance MAPK and both ERK and JNK activity, and lead to the phosphorylation of cPLA2 upon TNF α treatment. Additionally, MADD can induce TNF α gene expression and promote TNF α -induced proliferation of Kaposi's sarcoma (KS) cells, which can be inhibited by blocking MADD transcription. The GDP-GTP exchange protein (GEP), a rat homolog of IG20, mediates conversion of GDP-bound inactive form of the Rab-3 subfamily of small G proteins into the GTP-bound active form. Characterization of Rab3 GEP knockout mice showed that the protein is required for vesicle trafficking at the neuromuscular junction and might play a role in the formation of synaptic vesicles. Rab3 GEP $^{-/-}$ mice fully develop but die shortly after birth. A related gene with minimal sequence homology to MADD is the AEX gene of the *C. elegans*. When the above human

cDNAs were identified it was not apparent whether they represented products of related but distinct genes or different splice variants arising from a single gene.

[0005] Expression studies and sequence comparisons between cDNAs and with human genome data base showed that the above mentioned human cDNAs are splice variants encoded by the IG20 gene. The IG20 gene consists of 36 exons that range in size from 47 to 986 nucleotides, including the 5' and 3' un-translated regions. The IG20 splice variants result from alternative splicing of only exons 13L, 16, 21, 26, and 34. Human genome sequencing has revealed that the biological complexity seen in humans, relative to other species, is due to a higher degree of alternative splicing in human genes that could result in multiple proteins with different functions from the same gene.

[0006] In an attempt to understand the functional relevance of different splice variants of IG20 gene, HeLa cells were reported because they express all four splice variants, namely, IG20, MADD, IG20-SV2 and DENN-SV, detected to date in human cells and tissues. HeLa cell lines permanently transfected with cDNAs encoding IG20, MADD, and DENN-SV were assessed for TNF α -induced cell death. Consistently, relative to controls, HeLa-IG20 cells were most susceptible and HeLa-DENN-SV cells were most resistant to TNF α -induced cell death. Results obtained with HeLa-MADD cells were comparable to those obtained with HeLa cells transfected with an empty vector.

[0007] To understand why cells transfected with different splice variants of IG20 gene responded differently to TNF α treatment, potential functional motifs in the spliced regions were sought. An extensive search failed to reveal any apparent functional domains in the spliced regions. This suggested that splicing most likely results in conformational changes that affect their cellular localization or interactions with other proteins. Upon treatment with TNF α , all variants could interact with TNFR1 and enhance ERK activation. Differences in response to TNF α treatment of cells transfected with different IG20 splice variants are most likely not due to differences in these properties.

[0008] TNF α induced cell death is mediated through recruitment of FADD to the TNFR1/TRADD complex and activation of initiator caspase 8. Activation of caspase 8 leads to the activation of effector caspase 3 that cleaves a wide range of substrates ultimately leading to cell death. Upon treatment with TNF α /CHX, HeLa-IG20 cells showed maximal caspase activation. As expected, HeLa-Vector and HeLa-MADD

cells showed only a moderate activation of caspase 8. Surprisingly, HeLa-DENN-SV cells showed little, if any, caspase 8 activity upon identical treatment. Consistent with these data, higher and lower levels of cleaved-active caspase 8 and caspase 3 were noted in HeLa-IG20 and HeLa-DENN-SV cells, respectively, compared to control cells. Activation of caspases was critical by inhibiting cell death in the presence of CrmA, which preferentially inhibits caspases 1 and 8 and thus can block activation of caspase 3 and prevent TNF α -induced cell death. IG20 appears to be acting primarily upstream of caspase-8 and its interaction with TNFR1 can enhance TNF α -induced caspase 8 activation. This also indicated that enhancing caspase activation is the dominant function of IG20 since it can override its own up-regulation of ERK activation commonly associated with cell survival.

[0009] Although the IG20 gene can encode multiple splice variants that are functionally different, how many are naturally expressed in various human tissues was not known prior to the present disclosure. Whether splice variants (e.g. DENN-SV) that are highly expressed in tumors contribute to enhanced cell proliferation and/or resistance to cell death was unknown.

[00010] IG20 and IG20-SV2, and the previously reported KIAA0358, MADD, and DENN-SV are splice variants of the *IG20* gene, which is localized to chromosome 11p11 and consists of 36 exons. Differences among the above variants are due to alternative splicing of exons 13L, 16, 21, 26 and 34. Cell transfection studies showed that IG20 and DENN-SV conferred susceptibility and resistance respectively, to TNF α -induced apoptosis, whereas, MADD expression had no discernible effect. All three variants interacted with tumor necrosis factor type 1 (TNFR1) and enhanced activation of the extracellular-regulated kinase (ERK), but only IG20 enhanced activation of caspases 8 and 3. Further, IG20-mediated, TNF α -induced apoptosis could be abrogated by the caspase inhibitor, CrmA. These results suggested that enhancement of apoptosis by IG20 is mainly dependent on activation of caspases 8 and 3. In addition, several studies have implicated a role for *IG20* splice variants in tumor formation. However, to date, no systematic study has been conducted to determine which variants are naturally expressed in human tumors and whether they might influence tumor cell growth and/or susceptibility to various treatments leading to induced cell death.

- [00011]** The tumor necrosis factor (TNF) super family of ligands and receptors play a critical role in the regulation of organogenesis, homeostasis, inflammation, innate, and adaptive immunity. A subset of TNF family ligands can bind to their cognate death receptors on cells and activate apoptosis. Inappropriate regulation of apoptosis could result in chronic inflammation, autoimmunity, or development of cancer.
- [00012]** TNF Related Apoptosis Inducing Ligand (TRAIL) can selectively kill some cancer cells and render others susceptible to co-treatment with drugs and irradiation, with little or no effect on most normal cells. TRAIL induced apoptosis is of considerable interest and has significant implications for developing novel cancer therapies.
- [00013]** The TNF Related Apoptosis Inducing Ligand (TRAIL) is a unique member of the TNF super family that can kill cancer cells selectively with little or no effect on most normal cells. Recombinant TRAIL, when systemically administered, can result in tumor shrinkage in vivo and in some cases, their complete elimination without resulting in any of the adverse systemic side effects often associated with TNF- α or CD95L. TRAIL, when used alone, can kill some tumor cell lines, however, its efficacy, when used in combination with chemotherapy and γ -irradiation, is high.
- [00014]** TRAIL can bind to 5 distinct receptors- Death Receptor 4 (DR4 or TRAILR-1), Death Receptor 5 (DR5 or TRAILR-2), Decoy Receptor 1 (DcR1, TRAILR-3, LIT or TRID), Decoy Receptor 2 (DcR2, TRAILR-4, TRUNDD) and Osteoprotegerin (OPG). Among these receptors, only DR4 and DR5 contain cytoplasmic Death Domains (DD) and are able to transduce apoptotic signals upon TRAIL binding. Although TRAIL can ligate both the DcR1 and DcR2, since their cytoplasmic tails lack a DD or have a partial DD, they are unable to transduce apoptotic signals. Little is known about OPG except that it is a soluble receptor and its association with TRAIL is relatively weak. Similar to TNF- α and CD95L induced signaling, upon TRAIL treatment, FADD and caspase-8 are recruited to the DR4 and DR5 death inducing signaling complexes (DISC). Thus TRAIL; TNF- α and CD95L induced apoptotic signaling pathways share some common features. Earlier, the ability of TRAIL to selectively kill cancer cells was attributed to the dominant negative effects of the decoy receptors (DcRs) expressed on normal, but not on cancer cells, that can compete for TRAIL binding. More recent studies have shown that factors other than DcR expression confer resistance to TRAIL induced cell death.

- [00015]** IG20, MADD and DENN-SV could increase activity of TNF- α induced Mitogen Activated Protein (MAP) Kinase and Extracellular Signal Regulated (ERK) Kinase. Their ability to promote apoptosis however, varied. The IG20 and the DENN-SV splice variants rendered cells more susceptible and resistant to apoptosis respectively, whereas, the MADD splice variant had little or no apparent effect. Additional studies showed that all the three splice variants could interact with the TNFR1 upon TNF- α treatment, but only HeLa cells transfected with IG20 splice variant showed enhanced activation of caspase-8 and -3 that could be blocked by CrmA. IG20 acts as a pro-apoptotic molecule in enhancing TNF- α induced apoptosis.
- [00016]** IG20 can directly interact with TNFR1 and TRADD, but not CD95 and FADD indicating a potential role in TNFR1, but not CD95, mediated signaling. Analyses of DD sequences from different adaptor proteins showed that the DD of IG20 is more homologous to the DDs of DR4 and DR5 than it is to the DD of TNFR1 and TRADD.
- [00017]** The contrasting effects of DENN-SV and IG20 on susceptibility to death inducing stimuli suggests that the eventual outcome of these signaling pathways in tumor cells is determined, at least in part, by a balance in the expression levels of these two proteins. Indeed, HeLa cells that normally express all 4 variants, upon treatment with TNF- α undergo apoptosis, however, approximately only one half of the cells die. When dying cells were separated, on the basis of expression of apoptotic markers, from living cells and tested for expression of various splice variants, it was noted that while cells undergoing apoptosis expressed higher levels of the IG20 the viable cells expressed higher levels of DENN-SV.
- [00018]** Radiation therapy takes advantage of the inherently unstable nature of tumors. The DNA lesions induced by γ -irradiation activate an intrinsic cellular pathway for dealing with DNA damage. Cells initiate a set of physiological responses thought to facilitate DNA repair processes that include cell cycle arrest in G1, S phase, and G2, a slowing of DNA replication, and increased transcription of genes encoding proteins that participate in DNA replication and repair. If the degree of damage suffered by a cell is extensive, then the apoptotic pathway is activated leading to cell death. At the molecular level, several pathways have been studied, including p53 dependent and p53 independent pathways. Other molecules involved in the response to DNA damage include ATM, ATR, DNA-PK, hCds1/Chk2 and p21. Molecular mechanisms that regulate DNA damage, remain unclear.

SUMMARY OF THE INVENTION

- [00019]** A novel human gene (IG20) encodes multiple splice variants. The gene is essential for survival of the animal (knockout mice die immediately after birth). Splice variants have very important biological functions, but differ in their ability to affect cell death, survival and replication. The IG20 splice variant is pro-apoptotic, anti-proliferative, and renders cells more susceptible to induced cell death (i.e. is a tumor suppressor).
- [00020]** IG20, or a fragment thereof, can be over expressed to control cell proliferation, cell cycle, and to render cells more susceptible to chemotherapy, radiation therapy or death receptor mediated cell death.
- [00021]** DENN-SV is pro-proliferative, anti-apoptotic, and renders cells more resistant to induced cell death (i.e. is an oncogene)
- [00022]** DENN-SV, or a fragment thereof, can be used to control cell proliferation, cell death and cell cycle, and to enhance survival and replication of primary cells such as beta cells, neuronal cells and others.
- [00023]** DENN-SV expression can be down modulated to reduce cell proliferation, affect cell cycle and increase susceptibility to treatment with chemotherapy, radiation therapy and death receptor mediated cell death.
- [00024]** Levels of these splice variants may be regulated to modulate functions of each other to affect cell cycle, death, and survival.
- [00025]** There are significant implications for cancer therapy, treatment of autoimmune diseases, stem cell therapy and establishment of cells and tissues that could be used for grafting, in the IG20/DENN-SV interactions.
- [00026]** Seven putative splice variants of the human *IG20* gene were identified. Four variants namely, IG20, MADD, IG20-SV2 and DENN-SV are expressed in human tissues with higher expression in tumors. While DENN-SV is constitutively expressed in all tissues, expression of IG20 appears to be regulated. Interestingly, over expression of DENN-SV enhanced cell replication and resistance to apoptosis induced by *e.g.* treatments with TNF-alpha, vinblastine, etoposide and gamma-radiation. In contrast, IG20 expression suppressed cell replication and increased susceptibility to the above treatments. Moreover, cells that were resistant and susceptible to TNF-alpha induced apoptosis exclusively expressed endogenous DENN-SV and IG20 respectively. When PA-1 ovarian cancer cells that are devoid of endogenous IG20 variant, but express higher levels of DENN-SV, were transfected with IG20, they

showed reduced cell proliferation and increased susceptibility to apoptosis induced by TNF- α , TRAIL, and gamma-radiation. This indicated that over-expression of IG20 can override endogenous DENN-SV function. CrmA reversed the effects of IG20, but not DENN-SV. In contrast, dominant negative-I-kappa B reversed the effects of DENN-SV, but not IG20, and showed that DENN-SV most likely exerted its effects through NF-kappa B activation. *IG20* gene plays a novel and significant role in regulating cell proliferation, survival and death through alternative mRNA splicing.

[00027] Additionally, while CrmA reversed TNF α induced apoptosis in cells expressing IG20, dominant-negative IB α , which inhibits NF κ B activation, reversed DENN-SV-mediated resistance to apoptosis. Transfection of cDNA encoding a IG20 variant into cells of an ovarian cancer cell line that do not naturally express it, led to a significant decrease in their proliferation and a marked increase in susceptibility to various apoptosis-inducing agents. Collectively these studies show that IG20 expression can be used to render cells susceptible to apoptosis with potential implications for cancer therapy.

[00028] IG20 renders cells more susceptible to TRAIL induced apoptosis, which is inhibited by caspase inhibitors, p35 and CrmA, and dominant negative Fas associated death domain containing protein (FADD). Results from co-localization and immunoprecipitation studies showed that IG20 can interact with both TRAIL death receptors (DR), DR4 and DR5. Moreover, IG20 increased recruitment of FADD and caspase-8 into the TRAIL death inducing signaling complex (DISC). These results indicate that IG20 is a pro-apoptotic signaling molecule that has a novel function in enhancing TRAIL induced apoptosis by facilitating DISC formation.

[00029] Over-expression of DENN-SV and IG20 in HeLa cells conferred resistance and susceptibility, respectively, to the effects of γ -irradiation. HeLa IG20 cell susceptibility was due to enhanced apoptosis and reduced cell growth. This growth suppression was mediated by secreted soluble factors. Although HeLa DENN-SV cells grew more rapidly than control cells, replenishment with conditioned media (CM) from HeLa IG20 cells suppressed their growth. In addition, the CM from HeLa IG20 cells stopped the growth of ovarian PA-1 cancer cells in the G1-G0 cell cycle stage. Amongst an array of cytokines tested, IL-6 was found at the highest levels in HeLa IG20 culture supernatants, and IL-6 neutralization showed that it was in part responsible for the cell growth suppression. HeLa IG20 cells had elevated basal NF κ B

levels, a known regulator of IL-6 transcription. IG20 over-expression enhanced the combined apoptotic effects of TRAIL and γ -irradiation on HeLa cells.

[00030] HeLa cells stably transfected with DENN-SV YFP suppresses TRAIL apoptosis. Over-expression of DENN-SV can enhance resistance to TRAIL induced death (including other death ligands) at different concentrations of TRAIL. The kinetics of death induction is slower in these cells.

[00031] Treatment of cells with Si RNA against the middle portion of the DENN-SV, but not against the death domain (DD) of DENN-SV suppresses the levels of DENN-SV RNA. Cells treated with the Si RNA (against the middle portion whose sequence is given) undergo spontaneous apoptosis. The cells that fail to undergo spontaneous death after Si RNA induction are more susceptible to TNF-alpha induced apoptosis. The same enhanced susceptibility to treatment with other death receptor ligands is expected.

[00032] The normal mouse embryonic fibroblasts that are devoid of all splice variants of IG20 (from IG20 knockout mice; Rab3 GEP knockout mice), unlike human tumor cells do not undergo spontaneous apoptosis but are highly susceptible to TNF-alpha and FAS induced apoptosis. Anti-sense treatment could selectively kill tumor cells without affecting normal cells.

[00033] Various methods of treatment that can lead to over-expression of IG20 gene or cDNA expression and prevention of splicing that results in larger amounts of IG20 accumulation in the cell are disclosed. A method to selectively prevent splicing of IG20 is performed with anti-sense oligos directed against the splice region or through manipulation of other unidentified IG20 splice factors. This can also be accomplished either through transfection of the whole, or portions of the protein/peptides. A similar effect can be accomplished through silencing of DENN-SV using Si RNA, anti-sense RNA, other oligonucleotides, DENN-SV protein or its fragments that can act as dominant negatives, and the like. Results described herein show the use of DENN-SV to facilitate cell survival and growth of primary cells such as beta cells in the islet of Langerhans (insulin producing cells), neuronal cells, stem cells, and the like.

DEFINITIONS

[00034] IG20, Insulinoma-Glucagonoma clone # 20, MADD

[00035] MAP- Kinase Activating DeathDomain containing protein

[00036] DENN-SV, Differentially Expressed in Normal and Neoplastic cells - Short Variant

- [00037] TRAIL, TNF Related Apoptosis Inducing Ligand
 [00038] DR4/5- Death Receptor 4/5
 [00039] DcR1/2, Decoy Receptors ½
 [00040] DISC, Death Inducing Signaling Complex

BRIEF DESCRIPTION OF THE DRAWINGS

- [00041] **FIG. 1:** Shows some of the known signaling pathways that are activated upon TNF- α binding to TNFR1. IG20 causes enhanced recruitment of FADD and caspase 8 leading to enhanced apoptosis. In contrast, DENN-SV does not promote FADD/caspase 8 recruitment but leads to enhanced activation of NF κ B and cell survival pathway. All variants can activate various kinases indicating that this might not distinguish IG20 from DENN-SV.
- [00042] **FIG 2: Human *IG20* splice variants generated by alternative mRNA splicing.** The cDNA sequence homology among the seven *IG20* splice variants is shown. Solid bars represent regions of complete homology between all variants. Empty areas indicate exons 13L, 16, 21, 26 and 34, which, when spliced in different combinations, produce the seven splice variants shown on the left. Splicing of exon 34 in KIAA0358 and IG20-SV4 induces an early stop codon in exon 35. Shown also are different 5' untranslated regions (UTRs) for different splice variants.
- [00043] **FIG. 3: RT-PCR of mRNA from human tissues using IG20 primers.** Fifty seven samples representing normal, benign and malignant forms from ten different human tissue types were used to extract mRNA and perform RT-PCR. This was accomplished using exon specific primers, as described in the Materials and Methods. Several samples from the same tissue type were used; however, only one representative of these samples is presented in this figure. The splicing patterns of exons 13L, 16, 21, 26 and 34 for each of the tissues tested are shown.
- [00044] **FIG. 4: Relative intensities of cDNAs corresponding to *IG20* splice variants in transfected cells.** mRNAs from 293T cells stably transfected with IG20, MADD, IG20-SV2, and DENN-SV variants were extracted and 100ng of each sample was used for RT-PCR as described in the Materials and Methods. RT-PCR products were subjected to PAGE using a 5% gel and stained with ethidium bromide. (A) Quantitation of band intensities was performed using ImageQuant analysis. Intensities were calculated as the percent intensity of the band corresponding to a specific IG20 variant to the total intensities of all bands within the same sample. Shown are means and standard deviations from three independent groups of cells transfected separately.

P values were < 0.05 for all test groups. (B) Shows PAGE photos for one of the transfections used to generate data shown in (A).

[00045] **FIG. 5: Expression of 6-Histidine-tagged IG20 splice variants** shows the expression of the four transfected IG20 cDNA constructs fused to a sequence encoding the 6-Histidine tag at the 5' end. The tagged proteins, seen at about 215 kDa, as expected, correspond to the transfected cDNAs of IG20 splice variants, indicating that the proteins were encoded by the transfected cDNAs.

[00046] **FIG. 6: Effects of Dominant Negative-I κ B and CrmA on TNF- α induced, IG20-mediated apoptosis.** Blocking effects of DN κ B α and CrmA on the pro-apoptotic and anti-apoptotic effects of IG20 and DENN-SV are shown. Percentages represent mitochondrial depolarization (used as an indicator of apoptosis) due to TNF- α and cyclohexamide treatment; this was calculated by subtracting percentage of TMRE-negative cells transfected with either empty vector or with vectors containing either CrmA or DN κ B α , from percentage of TMRE-negative cells transfected with the same construct buttreated with TNF- α and cyclohexamide. TMRE data were obtained from GFP-positive gated cells only. Data shown in the figure represent three different wells for each sample. Experiment was repeated at least three times and consistent results were obtained. P values were < 0.05 for all test groups.

[00047] **FIG. 7: Endogenous Expression of IG20 variants and Susceptibility To TNF-Induced Apoptosis.** (A) Magnetic Separation of Apoptotic and TNF α - resistant Cells. Apoptotic cells were magnetized and physically separated from TNF α -resistant cells using the Annexin V-conjugated microbeads, as described in Materials and Methods. mRNAs were then isolated from apoptotic and TNF α -resistant cells separately and were used in RT-PCR using IG20-specific primers F-1 and B-1. The figure shows very little expression, if any, of IG20 (the pro-apoptotic variant) in cells resistant to TNF α -induced apoptosis, compared to control cells. In contrast, marked increase in expression of IG20 with no expression of DENN-SV (the anti-apoptotic variant) is seen in apoptotic cells. (B) TNF α -Induced Mitochondrial Depolarization in apoptotic and TNF α -resistant cells. Cells in(A) were then assessed for mitochondrial depolarization. As shown in the figure, maximal differences were seen in separated cells vs. un-separated control cells. Bars represent averages from three wells for each group. The experiment was repeated at least three times and consistent results were

obtained. These results were statistically significant, as p values were < 0.05 for both resistant and apoptotic groups relative to controls.

[00048] FIG. 8: Effect of IG20 and DENN-SV on Cell Survival and Apoptosis of Transfected Cells after Vinblastine Treatment. (A) Cell survival after Vinblastine treatment. The figure shows crystal violet staining of cell colonies two weeks after treatment with the indicated doses of vinblastine. (B) Vinblastine-Induced apoptosis. Cells treated with $0.05\mu\text{M}$ vinblastine were stained with Hoechst 24 hours after the treatment in order to determine the percentage of cells with condensed chromatin. P values were < 0.05 for all test groups.

[00049] FIG. 9: Effects of IG20 and DENN-SV on survival and proliferation of cells treated with etoposide. (A) Cell survival after etoposide treatment. Cells were treated with the indicated doses of etoposide and allowed to grow in culture for 2 weeks and stained with crystal violet. (B) Enumeration of colonies after etoposide treatment. Three different experiments using the indicated doses of etoposide were used to determine the effects of the drug on HeLa-control, HeLa-IG20 and HeLa-DENN-SV cells. P values were < 0.05 for all test groups. (C) Etoposide-Induced apoptosis. Cells treated with the indicated doses of etoposide were stained with Hoechst as described in Materials and Methods and evaluated for chromatin condensation under a microscope. P values were < 0.05 for all test groups. (D) Cell Division after Etoposide Treatment. Cells were stained with CFDA and then subjected to $5\mu\text{M}$ etoposide treatment for 5 days. Cells were then harvested and evaluated by FACS for CFDA staining intensity. Histograms show relative levels of CFDA dye retention. The peak on the left within each histogram represents cells that have undergone cell division, and therefore, partially lost CFDA staining, whereas the peak on the right represents undivided cells that retained maximum CFDA staining.

[00050] FIG. 10. Effects of IG20 and DENN-SV on HeLa cell growth and colony formation in soft agar. (A) Growth rates of HeLa-control, HeLa-IG20 and HeLa-DENN-SV cells. 1×10^5 cells/plate were plated in 100 mm^2 dishes in DMEM with 10% FCS. Cells were harvested and counted on the indicated days after plating. Data are presented as mean \pm 3 standard deviation of triplicate plates. P values were < 0.05 for all test groups. (B) Colony formation in soft agar. HeLa-control, HeLa-IG20, and HeLa-DENN-SV cells were plated in soft agar as described in Materials and Methods. Three weeks later, growth in soft agar was observed at a magnification of 10X. Photos show representative fields from each cell type. (C) Enumeration of colonies shown in

(B). Ten randomly selected fields of equal size were used to count cell colonies. P values were < 0.05 for all test groups.

[00051] FIG. 11: Expression of IG20 in HeLa and PA-1 cells. Shown are RT-PCR products using mature poly A+ mRNA extracted from HeLa and PA-1 cell lines. IG20 F-1 and B-1 primers that flank exons 13L and 16 were used as described in Materials and Methods. The figure demonstrates that cDNA bands that correspond to the four IG20 splice variants (i.e., IG20, MADD, IG20-SV2, and DENN-SV) are expressed in HeLa cells, whereas only MADD and DENN-SV are expressed in PA-1 cells.

[00052] FIG. 12: Effects of IG20 on PA-1 Cell Phenotypes. (A) Growth Rates. PA-1 and PA-1-IG20 cells were plated as described in Materials and Methods. Cells were then harvested and counted on the indicated days. Data are presented as mean + standard deviation of three plates for each sample. P values were < 0.05 for all test groups. (B) TNF α -Induced Apoptosis. Cells were either untreated or treated with TNF α and cyclohexamide (CHX) for three hours, as described in Materials and Methods and then tested for percentages of cells with active caspase 3. (C) TRAIL-Induced Apoptosis. Cells were either untreated or treated with TRAIL for three hours and then tested for percentages of cells with active caspase 3, in the presence or absence of Z-VAD, an inhibitor of caspase activation. (D) Response to α -radiation and TRAIL Treatment. PA-1-IG20 cells exposed to 6 and 12Gy of α -radiation were plated as described in Materials and Methods. Twenty-four hours later, cells were either untreated or treated with TRAIL for 3 hours. All cells were then harvested and tested for levels of active caspase 3. (E) TNF α -and TRAIL-Induced NF κ B Activation. Cells transfected with the NF κ B-luciferase reporter were serum-deprived and then subjected to mock, TNF α , TRAIL or zVAD treatments for 5 hours. Cells were then lysed and tested for levels of luciferase activity. Activity is presented as the levels of luciferase activity under treatment over the levels of activity under no treatment.

[00053] FIG. 13: IG20 transfected HeLa cells show increased apoptosis upon TRAIL treatment. HeLa-IG20 and control cells were treated for 5 hours with TRAIL at 100 ng/mL or with 10 ng/mL of TNF- α and 10 μ g/mL of Cycloheximide and analyzed for apoptosis. A) Activation of caspases - cells were incubated for 10 minutes with FITC labeled general caspase inhibitor VAD FMK (Val-Ala-Asp-fluoromethyl ketone) and analyzed by FACS. Numbers in the histogram indicate percentage of FITC positive cells. B) Mitochondrial Depolarization - Loss of the dye

TMRE is indicative of mitochondrial depolarization and the numbers shown in the FACS histograms represent percentage of TMRE negative cells. All the above experiments were done in triplicates and results shown are representative histograms. C) Hoechst staining - Cells were stained with Hoechst (1 $\mu\text{g/mL}$) for 10 minutes. Brightly stained nuclei indicate condensed chromatin. D) Percentage of cells with condensed chromatin was calculated by counting 3 fields containing at least 200 cells each and error bars indicate mean \pm S.D.

[00054] FIG. 14: Relative expression and stability of TRAIL receptors in HeLa IG20 cells A) DR and DcR expressions - HeLa IG20 and control cells were stained with antibodies conjugated to FITC that specifically react with DR4, DR5, DcR1 and DcR2 (peaks shifted to the right), or isotype matched control antibodies, and analyzed by FACS. B) Brefeldin A treatment - Equal number of control and IG20 HeLa cells were left untreated or treated with 1 $\mu\text{g/mL}$ of Brefeldin A for either 3H or 6H. Cells were stained for DR5 surface expression. Representative histograms show comparable levels of DR5 surface expression in Brefeldin A untreated and treated cells.

[00055] FIG. 15: IG20 Cells show increased specific activation of caspases upon TRAIL treatment A) Initiator caspases - HeLa IG20 cells and control cells treated with TRAIL for 1H, were stained, with fluoro-chrome-conjugated peptide inhibitors of specific active caspases as indicated, fixed and analyzed by FACS. B) Caspase-8 cleavage - IG20 HeLa cells and control cells were treated with TRAIL for either 1H or 3H, lysed and immunoblotted for the 10 kDa cleaved product of active caspase-8 using the 6B6 monoclonal antibody. C) Caspase-3 activation - HeLa IG20 cells and control cells untreated or treated with TRAIL or TNF- α and cycloheximide for 5 hours, were collected, fixed and stained with an active caspase-3 Phycoerythrin (PE) conjugated monoclonal antibody and subjected to FACS analyses. Above data are representative of 3 experiments.

[00056] FIG. 16. IG 20 enhanced apoptosis can be inhibited by caspase inhibitors and DN FADD HeLa IG20 and control cells (1×10^5 per well in a 6 well plate) were co-transfected with GFP-F vector along with either Crm A, p35 or DN-FADD in the ratio of 1:10. Twenty-four hours post transfection, TRAIL was added at a concentration of 100 ng/mL for 5 hours and both treated and untreated cells were stained with PE-conjugated anti-caspase3 antibodies and subjected to FACS analyses. The data were obtained from only GFP positive cells and represent 2 independent experiments carried out in duplicate.

[00057] FIG. 17: IG20 co-localizes with DR4 in HeLa cells HeLa cells were co-transfected with IG20-YFP and DR4-CFP (5:1) in two-chamber culture slides. 10 μ M Z-VAD was added after 12 hours of transfection to prevent apoptosis and cells were observed under the Delta Vision deconvolution microscope under a 100X magnification. The deconvolved z-stack image of a single HeLa cell expressing DR4-CFP, IG20-YFP and the merged image which indicates co-localization of the expressed proteins. The inset, shown in the lower panel, indicates the magnified region on the stained cell surface.

[00058] FIG. 18: IG 20 interacts with DR4 and DR5 receptor A) 293T cells were transfected with DR4-Flag and IG20-His (lane 1) or DR4-Flag alone (lane 2). IG20 antibody (panel a) or Flag antibody (panel b) was used to IP the lysates from the transfected cells and Flag antibody was used for the western blot (WB) on all samples. B) DR5-Myc was co-transfected with IG20-His and an IG20 antibody (lane 1) or a Myc antibody (lane 2) was used to IP the cell lysates and subjected to WB. Proteins were visualized using either a His (panel a) or a Myc (panel b) antibody. C) . IG20-GFP (construct shown in E) was transfected along with DR4-Flag (panel a) or alone (panel b). A Flag (lane 1), or an IG20 (lane 2), antibody was used to IP the lysates. Proteins were visualized on WB using a GFP antibody. D) . IG20-GFP was transfected alone (lane 1) or with DR5-CFP (lane 2) and IG20 antibody was used to IP the lysates (lane 1, 2). Cells were transfected with DR5-CFP alone and DR5 antibody was used to IP the transfected lysates (lane 3). Proteins were visualized using a GFP antibody in WB (GFP antibody also reacts with CFP).

[00059] FIG. 19: Enhanced recruitment of caspase-8 into the DISC of HeLa IG20 cells. HeLa IG20 and control cells (1×10^7) were collected and treated with 1 μ g/mL of TRAIL for the indicated duration. Lysates from treated as well as untreated cells were normalized for protein content and the DISC was precipitated using a DR4 (A) or a DR5 (B) specific antibody. The immunoprecipitated samples were then immunoblotted using antibodies specific for caspase-8, FADD, DR4 or DR5. All blots were developed with ECL and exposed to the film for the same duration.

[00060] FIG. 20: Effect of IG20 and DENN-SV on outgrowth of HeLa cells following γ -irradiation. (A) Schematic representation of the splice variants of the full length *IG20* gene. Only 4 splice variants (IG20, MADD, DENN-SV and IG20SV2) are readily seen in many normal and cancer tissues and only IG20 and DENN-SV (large black arrows) modulate the death inducing signals of $\text{TNF}\alpha$, TRAIL and

chemotherapy drugs. (B) HeLa cells stably transfected with a control vector or DENN-SV or IG20 expressing vectors were subjected to 12 Gy of γ -irradiation. Cells were allowed to grow for two weeks, fixed and visualized for outgrowth. These results are representative of 3 experiments. The assay was also repeated using 2 different stably transfected HeLa populations (C) Control and HeLa IG20 cells were subjected to 6, 8, 12 Gy of γ -irradiation or were left untreated (CTL). Cells were then plated at 10^6 cells/p100 plate. Twenty-four hours later cells were assayed for the levels of active caspase 3. This result was representative of 2 experiments.

[00061] FIG. 21: Effects of IG20 splice variants on HeLa cell growth (A) Control, HeLa IG20 and HeLa DENN-SV cells (10^5 cells/plate) were plated in 12 well dishes (1.5mL/well) in DMEM with 10% FCS. Cells were counted and results expressed as the mean \pm SD of triplicate determinations. These results are representative of at least 3 experiments. (B) Cells plated as in (A) were loaded with CFSE on day 4 and harvested on day 7. The relative CFSE dilution was determined using flow cytometry.

[00062] FIG. 22: Effects of conditioned media (CM) from HeLa cells stably transfected with IG20 spliced variants. (A) HeLa IG20, HeLa DENN-SV and control cells (10^5 cells/p100 plate) were plated and allowed to grow for 7 days. HeLa DENN-SV and HeLa IG20 cells had their media replaced daily from day 4 to day 7 with conditioned media derived from HeLa IG20 and HeLa DENN-SV cells, respectively. At day 7 all cells were harvested and counted. These results were confirmed by repeating the experiment at least 3 times. (B) Day 4 HeLa DENN-SV, HeLa IG20 and control cells were stained with CFSE and harvested on day 7 and analyzed for CFSE content (B.I). Day 4 (II) HeLa DENN-SV and HeLa IG20 (III) cells were loaded with CFSE (2 plates per cell type). One plate from HeLa DENN-SV cells was replenished with CM from HeLa IG20 cells (II) and one plate from HeLa IG20 cells was replenished with CM from HeLa DENN-SV cells (III).

[00063] FIG. 23: The effect of CM from HeLa IG20 cells on the growth of PA-1 cells. (A) 5×10^5 PA-1 cells were plated in 12 well plates. Next day, medium was replaced with CM from HeLa IG20, HeLa DENN-SV and HeLa cells. PA-1 cells were incubated for 48 and 96 hours and cell numbers enumerated. These results are representative of at least 3 experiments. (B) 5×10^5 PA-1 cells were plated in p100 plates and the next day cells were stained with CFSE and cultured in CM from (I) control HeLa, (II) HeLa DENN-SV and (III) HeLa IG20 cells for 24 hours. CFSE

histograms (I, II, III) were overlaid with control PA-1 cells grown without media replacement (left histogram).

[00064] FIG. 24: The effects of CM from HeLa IG20 cells on mitosis of PA-1 cells.

Representative pictures from DAPI stained PA-1 cells (A) grown in regular culture medium or in the presence of CM from (B) HeLa control, (C) HeLa DENN-SV and (D) HeLa IG20 cells for 24 hours. White arrows indicate cells undergoing mitosis.

[00065] FIG. 25: The effect of CM from HeLa IG20 cells on the cell cycle progression of PA-1 cells. PA-1 cells were plated in 3 p100 plates (5×10^5 cells/plate). Control cells were harvested 24 hours later and analyzed for cell cycle progression (1). At this point media from remaining plates were replaced with CM from either HeLa control (2) or HeLa IG20 (3). 48 hours later cells were subjected to cell cycle analysis.

[00066] FIG. 26: IL-6 secretion and NF- κ B basal activity is upregulated in HeLa IG20 and not HeLa DENN-SV cells (A) 10^5 HeLa vector, HeLa DENN-SV and HeLa IG20 cells were plated in p100 plates in serum-free media. 4 days later, supernatants were assayed for the presence of IL-6. These are representative results from 3 experiments. (B) HeLa vector, HeLa DENN-SV and HeLa IG20 cells were co-transfected with a reporter NF- κ B luciferase plasmid and a renilla luciferase plasmid driven by a CMV promoter. Forty-eight hours later, cells were harvested, lysed and assayed for firefly luciferase activity that was then normalized to the renilla luciferase activity. These results are representative of 3 experiments.

[00067] FIG. 27: Reversal of the effects of CM from HeLa IG20 cells on cell growth using an IL-6 neutralizing antibody. PA-1 cells (5×10^5 cells/plate) were plated in 12 well plates. The next day, media were replaced with CM from control, HeLa IG20 and HeLa DENN-SV cells alone or along with neutralizing IL-6 antibody ($50 \mu\text{g/mL}$). 48 hours later, cells were harvested and counted.

[00068] FIG. 28: Effect of γ -irradiation and TRAIL treatment on active caspase 3 levels in control and HeLa IG20 cells. HeLa vector and HeLa IG20 cells were assayed for the percentages of cells harbouring the active form of effector caspases 3 as an indicator of apoptosis. Irradiated (12 Gray) cells were plated for 24 hours and were left untreated or treated with TRAIL for 3 hours. Then cells were harvested and tested for the presence of active caspases 3.

[00069] FIG. 29: Shows results of the mouse experiment.

- [00070] **FIG. 30: a. Expression of the DSV-YFP** was done by transfecting the construct in 293T cells. Lysates were then subjected to SDS-PAGE and immunoblotted with GFP antibody to detect the 250Kda fusion protein. b. Stable HeLa cell lines of DSV-YFP were confirmed for specific overexpression of the integrated DSV-YFP construct (lane 2, top panel) by RT-PCR analysis. RNA was also probed for GAPDH (lane 1, 2, bottom panel) as loading control.
- [00071] **FIG. 31: Stable DSV-HeLa cells and vector control cells were treated with 25ng/mL of TRAIL for 3H or left untreated.** The cells were then collected, fixed and stained for active caspase-3 and FACS analyzed for percentage of cells positive for caspase-3.
- [00072] **FIG. 32: Stable DSV-HeLa cells** were left untreated or treated with 3 different concentrations of TRAIL, for either 1.5h, 3.0h or 5.0 h. Cells were then collected, fixed and stained with anti-active caspase-3 PE antibody and analyzed by FACS.
- [00073] **FIG. 33: Mid si RNA region.** Total RNA was extracted from HeLa cells transduced with lentiviral vectors expressing control vector, Mid and DD siRNA regions after 24 and 48 hours post-transduction using Trizol (Life Technologies, Inc). 48 hours after transduction, the cells expressing the Mid siRNA region (5'-GTACCAGCTTCAGTCTTTC-3') show knockdown of the IG20 gene as compared to the control vector and DD transduced cells. 0.8 µg of RNA was used in the Superscript one-step RT-PCR (Life Technologies, Inc) using F2-B2 primers, which amplify all isoforms of the IG20 gene. GAPDH was used as an internal control for the RT-PCR. The PCR products were separated on a 1% agarose gel.
- [00074] **FIG. 34: Mid and DD si RNA.** HeLa cells transduced with lentiviral vectors expressing vector control, Mid and DD siRNA regions were monitored for apoptosis after 24 and 48 hours post-transduction. Apoptosis was measured by TMRM staining. Viral transduction was normalized by GFP expression and GFP positive cells were gated for the TMRM analysis.
- [00075] **FIG. 35: Surviving HeLa cells** (2.5×10^5) transduced with lentiviral vectors (for 48 hours) expressing vector control, Mid and DD siRNA regions were plated onto 6-well plates. 24 hours later viable cells were treated with the indicated concentrations of TNF- α for 3 hours and analyzed for apoptosis as measured by TMRM staining. Viral transduction was normalized by GFP expression and GFP positive cells were gated for the TMRM analysis.

[00076] FIG. 36: Rab3-GEP KO MEFs are susceptible to TNF α -induced apoptosis. Rab3-GEP KO and wild type mouse embryonic fibroblasts (MEFs) were treated for 4 hrs with 10 ng/ml of murine TNF- α (SIGMA) and 10 mcg/ml of cycloheximide. For testing levels of active caspase-3, MEFs were harvested, fixed and permeabilized. MEFs were stained with anti-active-caspase-3 PE-conjugated antibody and analysed by FACS for PE-positive population.

[00077] FIG. 37: Rab3-GEP KO MEFs are susceptible to Fas-induced apoptosis. Rab3-GEP KO and wild type mouse embryonic fibroblasts (MEFs) were treated for 8 hrs with anti-Fas mAb (clone Jo2, BD Pharmingen) alone or along with 10 mcg/ml of cycloheximide (CHx). For testing levels of active caspase-3, MEFs were harvested, fixed and permeabilized. MEFs were stained with anti-active-caspase-3 PE-conjugated antibody and analysed by FACS for PE-positive population.

DETAILED DESCRIPTION OF THE INVENTION

[00078] The IG-20 gene is essential for survival of animals. It is over-expressed in human tumors and cancer cell lines, and can encode 4 different splice variants. The DENN-SV splice variant is constitutively expressed in all cells and tissues, and is highly-expressed in human tumors and cancer cell lines relative to normal tissues and other splice variants. Cells transfected with a cDNA encoding DENN-SV proliferate more aggressively, form larger colonies in soft agar and become resistant to TNF- α , TRAIL, etoposide and vinblastine induced cell death. In contrast, cells transfected with a cDNA encoding IG20 splice variant become more susceptible to cell death induced by the above treatments and grow slowly in culture. In addition, the increased susceptibility of IG20 transfected cells to TNF- α and TRAIL induced death is mediated by the activation of caspases-8 and -3 resulting from enhanced recruitment of caspase 8 and FADD to the Death Inducing Signaling Complex (DISC). The other two splice variants, MADD and IG20-SV2, exhibit little or no effect. More interestingly, cells that lack IG20, such as PA-1-ovarian carcinoma cell line, proliferate rapidly and resist TRAIL induced apoptosis. However, after IG20 is introduced, they replicate slowly and become susceptible to TRAIL induced apoptosis. These observations clearly show that DENN-SV and IG20 are biologically very important. Differential expression of IG20 and DENN-SV splice variants renders cells either more susceptible or resistant to induced cell death respectively, and the pro-apoptotic property of IG20 variant can be exploited to render tumor cells that are

otherwise resistant to become susceptible to killing by TRAIL and/or chemotherapeutic agents.

[00079] HeLa cells were stably transfected with DENN-SV YFP construct and expression of the construct was confirmed in the cell line as shown in FIG. 30.

[00080] Stable transfection of HeLa cells with DENN-SV suppresses TRAIL apoptosis as shown in FIG. 31.

[00081] Caspase-3 Kinetics dose response and time course of TRAIL apoptosis is shown in FIG. 32. FIGS. 31-32 show that over-expression of DENN-SV can enhance resistance to TRAIL induced death (this is true for other death ligands as well) at different concentrations of TRAIL. These figures also show that the kinetics of death induction is slower in these cells.

[00082] FIG. 33 shows that treatment of cells with Si RNA against the middle portion of the DENN-SV, but not against the death domain (DD) of DENN-SV suppresses the levels of DENN-SV RNA (completely abrogates).

[00083] FIG. 34 shows that cells treated with the Si RNA (against the middle portion whose sequence is given) undergo spontaneous apoptosis.

[00084] The data in FIG. 35 show that those cells that fail to undergo spontaneous death after Si RNA induction are more susceptible to TNF-alpha induced apoptosis. The same enhanced susceptibility to treatment with other death receptor ligands is expected based on this study.

[00085] (FIGS. 36-37) show that normal mouse embryonic fibroblasts that are devoid of all splice variants of IG20 (from IG20 knockout mice; Rab3 GEP knockout mice), unlike human tumor cells do not undergo spontaneous apoptosis (as seen in FIG. 34) but are highly susceptible to TNF-alpha (FIG. 36) and FAS (FIG. 37) induced apoptosis. These results point to the differences between normal and tumor cells. They indicate that anti-sense treatment could selectively kill tumor cells without affecting normal cells.

[00086] The data shown in FIGS. 30-37 complement the earlier data (FIGS. 1-29), which showed that IG20 can act as a competitive antagonist and over-ride DENN-SV function. The data in FIGS. 30-37 show that the same effect can be elicited by down-modulating DENN-SV. Various methods of treatment that can lead to over-expression of IG20 gene or cDNA expression and prevention of splicing that results in larger amounts of IG20 accumulation in the cell are disclosed. A method to selectively prevent splicing of IG20 is performed with anti-sense oligos directed

against the splice region or through manipulation of other unidentified IG20 splice factors. This can also be accomplished either through transfection of the whole, or portions of the protein/peptides. The data in FIGS. 30-37 show that a similar effect can be accomplished through silencing of DENN-SV using Si RNA, anti-sense RNA, other oligonucleotides, DENN-SV protein or its fragments that can act as dominant negatives, and the like. Results disclosed herein show the use of DENN-SV to facilitate cell survival and growth of primary cells such as beta cells in the islet of Langerhans (insulin producing cells), neuronal cells, stem cells, and the like.

EXAMPLES

[00087] **Example 1: Ig20 Suppresses Tumor Cell Survival and Enhances their Susceptibility to Apoptosis and Cancer Drug**

[00088] FIG. 1 shows a model of a signaling pathway.

[00089] *Identification of IG20 Splice Variants*

[00090] Analyses of cDNA sequences (FIG. 2) showed that all seven variants of *IG20* identified to date arise from alternative splicing of exons 13L, 16, 21, 26, and 34. The full-length cDNA of IG20 (IG20-FL) (accession number AF440100) is 5995 base pairs (bps) long, consists of all 36 exons and represents the longest variant. Splicing of exon 34 alone generates KIAA0358 (accession number AB002356) that consists of 5942 bps. Splicing of exons 21 and 26, and splicing of exons 16, 21 and 26 generate 5878 bps long IG20 (accession number AF440101) and 6002 bps long MADD (accession number U77352) respectively. MADD is also known as DENN (accession number U44953) that is 5844 bps long. Splicing of exons 13L, 21 and 26, and 13L, 16, 21 and 26 generate 5749 bps long IG20-SV2 (accession number AF440102) and 5689 bps long IG20-SV3 (accession number AF440103) (earlier referred to as DENN-SV). Finally, splicing of all five exons (13L, 16, 21, 26 and 34) generates IG20-SV4 (accession number AF440434), which is the shortest variant and consists of 5619 bps. Sequencing of cDNAs from several tissues and cell lines confirmed that bands of the same size have identical sequences. Differences in nucleotide sequences among various variants are not limited to splicing of the above exons, and include nucleotide sequences upstream of the ATG start codon and downstream of the stop codon.

[00091] *Only IG20, IG20-SV2, MADD and DENN-SV are Expressed In Human Tissues*

[00092] Expression patterns of IG20 was examined in human tissues. mRNA from fifty-seven different human tissues and 14 different human cell lines was used in RT-

PCR using multiple sets of *IG20*-specific primers. Four different primer pairs were designed to amplify regions of *IG20* that contain alternatively spliced exons 13L, 16, 21, 26 and 34. FIG. 3 shows expression patterns of *IG20* variants in normal, benign and malignant forms of ten different human tissue types. To validate RT-PCR results and to identify specific splice variants, mRNAs from several samples of the same tissue type were used in RT-PCR and consistent results were obtained but only one representative sample for each tissue type is shown. Results further demonstrated that of the 36 exons only a select few undergo alternative splicing. Together, the above data show that up to 4 different *IG20* splice variants are expressed in different patterns and levels in all human tissues tested.

[00093] None of the tissues tested expressed three of the splice variants namely, KIAA0358, *IG20*-FL and *IG20*-SV4. KIAA0358 was identified as an EST and was isolated from a human brain library, whereas *IG20*-SV4 was isolated as a partial clone from a human insulinoma library. Similarly, expression of the full-length clone that contains all 36 exons has not been detected.

[00094] *All Four IG20, MADD, IG20-SV2, and DENN-SV Can Encode Proteins*

[00095] 293T cells with cDNAs encoding each of the four splice variants of *IG20* are expressed in human tissues. FIG. 4 shows levels of *IG20* cDNAs amplified from mRNA transcripts that correspond to the transfected *IG20* splice variant. Proteins encoded by these cDNAs were immunoprecipitated using anti-*IG20* polyclonal antibodies and subjected to Western Blotting using an anti-His monoclonal antibody. His-tagged *IG20* protein variants encoded by the transfected cDNAs were seen at the expected molecular weight of about 215 kDa (FIG. 5). Due to small differences in their coding sequences, these proteins have similar apparent molecular weights. These results showed that the transfected cDNAs could encode the corresponding proteins.

[00096] Susceptibility of HeLa cells transfected with each of the above described four *IG20* splice variants to TNF and cyclohexamide-induced apoptosis by trypan Blue exclusion, chromatin condensation, and mitochondrial depolarization. HeLa-*IG20* and HeLa-DENN-SV cells showed an increase and a decrease in TNF α -induced cell death respectively, whereas HeLa-MADD cells showed no significant difference in apoptosis relative to the controls. Interestingly, HeLa-*IG20*-SV2 cells showed a phenotype similar to that of HeLa-MADD and HeLa-control cells (i.e., no significant effects on apoptosis).

[00097] *Dominant-Negative I-KappaB-Alpha (DN-IκBα) Abrogates DENN-SV-mediated resistance to TNFα-induced apoptosis*

[00098] IG20 enhances TNFα-induced apoptosis by activation of caspases 8 and 3. To understand the mechanism by which DENN-SV confers resistance to TNFα-induced apoptosis, CrmA and DN-IκB were used that can block activation of caspases or NFκB, respectively. FIG. 6 shows that there was maximal inhibition of TNFα-induced apoptosis by CrmA in HeLa-IG20 cells relative to control cells, with little or no effect on HeLa-DENN-SV cells. In contrast, DN-IκBα significantly enhanced apoptosis in HeLa-DENN-SV cells and had minimal effects on HeLa-IG20 cells. Together, these results suggested that IG20 and DENN-SV play distinct roles in TNFα-induced signaling by activating either caspases that can be blocked by CrmA or NFκB that can be blocked by DN-IκBα, respectively.

[00099] *Endogenous Expression of IG20 Splice variants Correlates With Susceptibility to TNFα-Induced Apoptosis*

[000100] To see whether expression of endogenous IG20 and DENN-SV were associated with increased and reduced cell death respectively, cells that were susceptible (Annexin V-positive) were separated from those that were resistant (Annexin V negative) to TNFα-induced apoptosis, and the levels of expression of IG20 variants were compared. FIG. 7A showed that, relative to unseparated control HeLa cells, there was very little expression, if any, of IG20 (pro-apoptotic variant) and a much higher level of expression of DENN-SV (anti-apoptotic variant) in resistant cells. In contrast, cells undergoing apoptosis showed a very high level of expression of IG20 and undetectable levels of other variants. The percentages of cells with depolarized mitochondria were measured in these two subpopulations of cells, as another marker of apoptosis. As shown in FIG. 7B, maximum apoptosis (cells with depolarized mitochondria) (93 %) was noted in Annexin V-positive cells, whereas minimum apoptosis (8 %) was seen in Annexin V-negative cells, compared to unseparated control cells (35 %).

[000101] *IG20 and DENN-SV Exert Contrasting Effects on Cell Proliferation and Responses to Apoptosis-Inducing Agents*

[000102] HeLa-IG20 and HeLa-DENN-SV cells showed profound differences in their response to vinblastine treatment (FIGS. 8A and -B). HeLa-DENN-SV cells were not significantly affected when they were treated with a dose of 0.05 μM. In contrast,

there were only a few HeLa-IG20 colonies detectable indicating their enhanced susceptibility. HeLa-control cells showed an intermediary response. Additionally, Vinblastine-induced apoptosis was noted in 70 % and 21 % of HeLa-IG20 and HeLa-DENN-SV cells respectively, compared with 46 % of HeLa-controls, as measured by chromatin condensation.

[000103] Next, the response of these cells to treatment with different doses of etoposide was evaluated. On average, HeLa-IG20 cells formed 8 colonies after treatment with 5 μ M etoposide. In contrast, HeLa-DENN-SV cells formed as many as 125 colonies, compared to 39 colonies formed by HeLa-control cells (FIGS. 9A and B). Upon treatment with 20 μ M of etoposide, HeLa-IG20 cells formed very few or no colonies, whereas HeLa-DENN-SV cells formed approximately 40 colonies. In addition, as shown in FIG. 9A HeLa-DENN-SV cells were able to grow even after treatment with 30 μ M of etoposide. These results were further substantiated by assessing apoptosis (FIG. 9C) and cell division (FIG. 9D) after etoposide treatment. Expectedly, HeLa-DENN-SV cells displayed a noticeable resistance to etoposide-induced apoptosis. However, interesting results were obtained with HeLa-IG20 cells. They did not show a marked increase in susceptibility to apoptosis (FIG. 9C), but showed a significant decrease (9 %) in cell division as indicated by CFDA staining, compared to DENN-SV (36 %) and control (24 %) cells (FIG. 9D).

[000104] The growth rates of HeLa-IG20 and HeLa-DENN-SV cells indicated that HeLa-IG20 and HeLa-DENN-SV cells showed growth attenuation or rapid growth respectively, compared to HeLa-control cells (FIG. 10A). To evaluate their ability to grow in soft agar resulting in colony formation, cells were plated at different densities. On average, HeLa-DENN-SV cells and HeLa-IG20 cells formed 20 and 2 colonies respectively, while HeLa-control cells formed 4 colonies (FIGS. 10B and C). Additionally, HeLa-DENN-SV colonies were bigger, while HeLa-IG20 colonies were smaller, than HeLa-control colonies.

[000105] *Effects of IG20 Over-Expression on Cells That Do Not Express Endogenous IG20*

[000106] Results in FIG. 7 showed a clear correlation between the endogenous expression of IG20 and apoptosis. To study the effects of expression of IG20 variant on cells that do not naturally express it, PA-1, a human ovarian carcinoma cell line that expresses DENN-SV and MADD but not IG20 splice variant was used (FIG. 10).

- [000107]** IG20 caused PA-1 cells to grow at a rate 10 times slower than untransfected PA-1 cells (FIG. 12A). Additionally, IG20 renders PA-1 cells more susceptible to TNF α -induced apoptosis (FIG. 12B). More profound differences were seen with TRAIL (tumor necrosis factor-related apoptosis inducing ligand) treatment. PA-1 cells were almost completely resistant while PA-1-IG20 cells were highly susceptible to TRAIL-induced apoptosis (FIG. 12C). Interestingly, transfecting PA-1 cells with IG20 led to a ten-fold increase in spontaneous apoptosis over cells transfected with a control plasmid (10% vs. 0.98%). Similarly, IG20 rendered PA-1 cells more susceptible to treatment with radiation in combination with TRAIL (FIG. 12D).
- [000108]** Because IG20 not only enhanced cell death induced by different agents, but also suppressed cell proliferation, a question was whether cell survival signaling pathway was affected. The effects of IG20 on NF κ B activation upon TNF α treatment (FIG. 11-E) clearly showed that IG20 suppressed TNF α -induced activation of NF κ B, compared to control cells.
- [000109]** As shown in FIG. 2, only IG20, MADD, IG20-SV2 and DENN-SV, and not KIAA0358, IG20-SV4 and IG20-FL, are expressed in human tissues and could be of physiological relevance. The four variants expressed in human tissues arise from deletion of exons 21 and 26 (with the exception of a malignant pancreas) along with deletion of either exon 13L or 16, or both.
- [000110]** HeLa cells were permanently transfected with each of the four IG20 variants and showed the over expression of each of the four variants using a one-step internally controlled RT-PCR that simultaneously compares expression levels of all the four IG20 variants. Expression of the corresponding proteins were shown using anti-His antibodies.
- [000111]** Cells transfected with IG20 and DENN-SV were most susceptible and resistant to TNF α -induced apoptosis respectively, whereas cells transfected with MADD or IG20-SV2 did not show significant differences relative to cells transfected with a control plasmid. Because DENN-SV lacks both exons 13L and 16, MADD lacks exon 16 and IG20-SV2 lacks exon 13L, these results demonstrated that expression of both exons 13L and 16, as seen in IG20, is required for anti-proliferative and pro-apoptotic properties, whereas deletion of both exons, as seen in DENN-SV, is required for proproliferative and anti-apoptotic properties.
- [000112]** Differences in the expression of different variants were not due to indirect inhibitory effects of protein synthesis by cyclohexamide, since there was no

significant difference between cells that were either untreated or treated with cyclohexamide alone. Another important implication of these results is that they provide a possible explanation as to why maximal pro-apoptotic or anti-apoptotic effects are not observed in a heterogeneous HeLa cell population that is transfected with IG20 or DENN-SV respectively. This could also be due to mutual regulation of the function of IG20 and DENN-SV that are naturally co-expressed, *albeit*, at different levels in HeLa cells.

[000113] The effects of IG20 and DENN-SV on the apoptotic response to common cancer treatments showed HeLa-IG20 and HeLa DENN-SV cells were more susceptible and resistant respectively to vinblastine and TNF α treatment. However, HeLa-IG20 cells and HeLa-control cells showed a similar response to etoposide-induced apoptosis and yet had a fewer number of cells at the end of the observation period. This suggested that etoposide treatment might have suppressed the ability of HeLa-IG20 cells to proliferate. Cell proliferation data showed that HeLa-IG20 cells had reduced growth, compared to HeLa-control cells. Together, these results suggest that the apparent resistance of HeLa-DENN-SV cells to etoposide treatment is due to a combination of enhanced resistance to apoptosis and increased cell division, whereas the sensitivity of HeLa-IG20 is mainly due to a decreased rate of cell division.

[000114] HeLa-DENN-SV and HeLa IG20 showed greater and reduced proliferation respectively, relative to control cells. There was a difference in the anchorage-independent growth of both HeLa-DENN-SV and HeLa-IG20 cells compared to HeLa-control. DENN-SV cells formed higher numbers of larger colonies in soft agar indicating enhanced anchorage-independent growth. In contrast, HeLaIG20 cells showed reduced growth and formed smaller as well as fewer numbers of colonies in soft agar. These results provided further evidence of the contrasting effects of IG20 and DENN-SV on proliferation and cell survival.

[000115] The effects of expressing IG20 variant in cells of PA-1 human ovarian carcinoma cell line that do not naturally express it were examined. Relative to PA-1 cells, PA-1-IG20 cells showed significantly reduced proliferation and were much more susceptible to spontaneous, TNF α - and TRAIL-induced apoptosis. These cells were even more susceptible to a combined treatment with TRAIL and γ -radiation. Of interest is the finding that TRAIL, a member of the TNF superfamily, can induce

apoptosis in some tumor cells but not in others. This raises the possibility that IG20 could be used to render cells that are otherwise resistant to become susceptible (as seen with PA-1 cells) to TRAIL-induced cell death, and could have significant implications for cancer therapy. Percentages of cells with active caspases were somewhat less in PA-1 cells treated with 12 Gy+TRAIL relative to those treated with lesser doses (6 or 8 Gy+TRAIL).

[000116] In conclusion, results presented in this example provide a comprehensive analysis of alternative splicing of *IG20* gene and its differential expression in human normal and tumor tissues. There is clear evidence to suggest that IG20 and DENN-SV have contrasting effects on apoptosis and cell proliferation.

[000117] **Example 2: IG20 (MADD Splice Variant 5) a Proapoptotic Protein Interacts with DR4/DR5 and Enhanced TRAIL Induced Apoptosis by Increasing Recruitment of FADD and caspase -8 to the DISC.**

[000118] **HeLa cells transfected stably with IG20 show enhanced susceptibility to TRAIL induced apoptosis** - The degree of TRAIL induced apoptosis was determined using several different approaches, which included activation of caspases, mitochondrial depolarization and chromatin condensation. HeLa cells stably transfected with either IG20 or a control vector were treated with TRAIL for five hours. Earlier studies from the inventors' laboratory have shown that this duration of treatment is optimal for analysis of all three different cell death markers. As indicated in FIG. 13A, HeLa IG20 cells showed increased total caspase activation as determined by the binding of the broad spectrum caspase inhibitor, Z-VAD conjugated to FITC, increased mitochondrial depolarization as detected by the dye TMRE (FIG. 13B) and higher percentage of cells that were positive for Hoechst staining indicating chromatin condensation (FIG. 13C). A similar increase in apoptosis of IG20 cells upon treatment with TNF- α and cycloheximide was observed. There was, however, an approximate 3-3.5-fold increase in cells undergoing apoptosis after TRAIL treatment relative to only a two-fold increase after TNF- α treatment. IG20 can enhance TRAIL induced apoptosis to a higher magnitude relative to the enhancement seen after TNF- α and cycloheximide treatment.

[000119] **Control and IG20 stably transfected cells display similar surface expression of TRAIL receptors** - Differential susceptibility of normal primary cell lines versus transformed cell lines to TRAIL was initially attributed to the presence of at least one decoy receptor in normal cells, but its absence in tumor cell lines. The

DcR1 and DcR2 decoy receptors attenuate TRAIL induced signaling by competing for the ligand binding to DR4 and DR5. Therefore, the relative levels of expression of different TRAIL receptors could profoundly affect the ability of TRAIL to induce apoptosis. To rule out the possibility that IG20 may affect the levels of expression of these receptors, surface expression was analyzed. As seen in FIG. 14A, the levels of expression of all four receptors were comparable in both control and HeLa IG20 cells, indicating that stable expression of IG20 had no significant effect on the surface expression of various TRAIL receptors.

[000120] Receptor stability in IG20 HeLa cells - a delay in the death receptor turn over could accentuate sensitivity of HeLa cells to TRAIL induced apoptosis. In order to test the possibility that HeLa IG20 cells might have a slower rate of receptor turnover than the controls, cells were treated with Brefeldin A, which blocks Golgi function and prevents receptor replenishment on the cell surface. Treatment of both HeLa IG20 and control cells with Brefeldin A showed no difference in the stability of DR5 on the cell surface (FIG. 14B) either at three or six hours, indicating that differences in the rate of receptor turnover was not responsible for the enhanced apoptosis of HeLa IG20 cells.

[000121] HeLa IG20 cells show increased activation of initiator and effector caspases - Addition of TRAIL results in receptor clustering, which facilitates FADD and caspase-8 recruitment leading to effector caspase-3 activation. In order to analyze whether IG20 mediated itseffects by increasing activation of caspases, levels of caspase-8, were tested which is the main activator caspase involved in TRAIL mediated death pathway. Caspase-10, a molecule with sequence similarity to caspase-8 has been shown to participate with caspase-8 in the DR4 and DR5 signaling pathways and therefore their levels in TRAIL treated cells were determined. As seen in FIG. 15A, the levels of both caspases, measured in fluorescence intensity, increased in TRAIL treated HeLa IG20 cells compared to TRAIL treated control cells. Cleavage of Pro-Caspase-8 results in active caspase-8 and a 10 kDa fragment (p10) that can be readily detected in a western blot using a p10 specific antibody. An increase in the amount of cleaved caspase-8 is seen in HeLa IG20 cells relative to the control cells tested at different timepoints after TRAIL treatment (FIG. 15B). The blot was also stripped and reprobed with anti- β -actin to ensure equal protein loading.

[000122] Activated caspase-8 could cleave cytoplasmic Bid, which can subsequently translocate to the mitochondria leading to activation of the mitochondrial pathway and

caspase-9. Therefore, for caspase-9 activation was tested and consistent with the results obtained from TMRE staining (FIG. 13B), upon TRAIL treatment, activation of caspase-9 was increased in HeLa IG20 cells relative to control cells (FIG. 15A).

[000123] Caspase-3, the main downstream effector caspase, is activated either directly by active caspase-8, or indirectly through Bid cleavage leading to the activation of mitochondrial pathway and caspase-9. The levels of active caspase-3 in HeLa IG20 as well as control cells were measured by staining treated cells with a specific anti-active caspase-3 PE conjugated antibody. As seen in FIG. 15C, IG20 HeLa cells showed considerably higher levels of caspase-3 activation relative to control cells. The relative increase in caspase-3 activation was more profound in TRAIL treated HeLa IG20 cells relative to control cells (five fold increase), when compared to cells treated with TNF- α (less than two fold increase). These results show that IG20 can promote activation of caspases-8 and-10 on one hand and caspase-9 on the other, perhaps both contributing to the activation of caspase-3 and enhanced apoptosis.

[000124] **TRAIL induced apoptosis can be inhibited by caspase inhibitors and DN-FADD** - There was increased activation of caspases in HeLa IG20 cells relative to control cells after TRAIL treatment. In order to further confirm the necessity of caspases for enhanced apoptosis in HeLa IG20 cells, and to begin to identify the potential site of action of IG20 in the signaling pathway, caspase inhibitors, p35, a baculovirus derived general caspase inhibitor and CrmA, a poxvirus protein that can inhibit caspase-8 and -1 preferentially were used. Both p35 and CrmA abrogated TRAIL induced apoptosis in both control as well as IG20 cells (FIG. 16). FADD is an essential upstream adaptor molecule that is required for the recruitment of caspase-8 in TRAIL induced apoptosis. Therefore, the levels of active caspase-3 were assessed as a marker of apoptosis in control and HeLa IG20 cells transfected with a DN-FADD and these cells were almost completely resistant to TRAIL induced apoptosis (FIG. 16). Since both the caspase inhibitors and the DN-FADD rendered HeLa IG20 cells highly resistant to TRAIL induced apoptosis, the function of IG20 in TRAIL induced apoptosis required functional caspase-8.

[000125] **IG20 co-localizes with DR4 in HeLa cells** – Caspase-8 and FADD are two signaling molecules that are proximal to DR4/DR5 and are required for TRAIL induced apoptosis. IG20 does not interact directly with FADD (23), but requires intact FADD and caspase-8 to mediate its effects. In addition, IG20 DD has a high homology to the DDs of DR4 and DR5. Co-localization studies were conducted using

IG20-YFP and DR4-CFP constructs. These proteins were expressed in 293T cells and immunoblotted using a GFP antibody to check for spontaneous cleavage of the fluorescent tags. Both constructs expressed expected size fusion proteins with no detectable cleavage of either YFP or CFP. Over expression of death receptors in vivo results in spontaneous oligomerization resulting in apoptosis of cells. Similarly, the DR4-CFP construct caused apoptosis when over expressed in HeLa cells. To minimize spontaneous cell death due to receptor over expression, levels of expression were optimized by lowering its ratio with respect to IG20-YFP in co-transfection experiments. As seen in FIGS. 17A and B, both fusion proteins were simultaneously expressed in the cotransfected HeLa cells. The expression of DR4-CFP is restricted mostly to the membrane, but also is found in the cytoplasm as indicated by a series of Z- stack pictures captured in the CCD camera. FIG. 17C is an overlay image, which demonstrates that the two proteins are co-localized.

[000126] DR4 and DR5 interact with full length and the middle fragment of IG20 -

To more directly demonstrate that IG20 can interact with DR4 and DR5 and to further extend the co-localization data, 293T cells were co-transfected with the IG20-His and a DR4-Flag or a DR5-Myc construct. Immunoprecipitation of lysates from transiently transfected 293T cells was carried out using either a polyclonal IG20 peptide antibody or a Flag specific antibody. As seen in FIG. 18A, immunoprecipitate (IP) using an anti-IG20 peptide antibody from lysates of IG20-His and DR4-Flag co-transfected cells (panel a, lane 1), but not of cells transfected with DR4-Flag alone (panel a, lane 2), showed association of DR4-Flag protein with IG20. Similarly, Myc specific antibody co-precipitated IG20-His (FIG. 18B, panel a, lane 2) and the IG20 antibody immunoprecipitated DR5-Myc (FIG. 18B, panel b, lane 1) from lysates of cells co-transfected with IG20-His and DR5-Myc, suggesting that IG20 can interact with DR5. In order to further confirm these results, a GFP fusion construct of IG20, that contains all the splice sites observed to date at the N-terminal end and the death domain at the C-terminal end (FIG. 18E) was used. As seen in FIG. 18C, the 125 kDa IG20-GFP was immunoprecipitated using the Flag specific antibody only from lysates of cells co-transfected with IG20-GFP and DR4-Flag (FIG. 18C, panel a, lane 1), but not from IG20 transfected cells alone (FIG. 18C, panel b, lane 1). Immunoprecipitation of lysates from cells co-transfected with IG20-GFP and DR5-CFP with IG20 antibody showed the presence of both proteins confirming that IG20 interacts with DR5 (FIG. 18D, lane 2). Together these results showed that IG20

interacts with both DR4 and DR5 and the IG20 domain that interacts with the DRs lies within the 748 amino acid residues that constitute IG20.

000127] Recruitment of Caspase-8 and FADD to the DR4 and DR5 DISC is increased in HeLa IG20 cells – TRAIL induced signaling through DR4 and DR5 results in the formation of DISC that contains FADD and Caspase-8, which are the main proximal initiators of apoptosis. Moreover, IG20 interacts with the DR4 and DR5. Therefore, one possible mechanism by which IG20 can render cells more susceptible to apoptosis is through enhanced TRAIL DISC formation. The TRAIL DISC was immunoprecipitated from lysates (equalized for protein) of control or HeLa IG20 cells using anti-DR4 and anti-DR5 antibodies after TRAIL treatment for the indicated periods of time. As seen in FIG. 19A, there is an increased recruitment of procaspase-8 into the DISC from HeLa IG20 cells relative to control cells. Furthermore, increased cleavage of procaspase-8 into its active p43/41 fragments was also evident. This effect was time dependent and correlated well with the previous results, which showed an increase in the processed p10 form of caspase-8 in HeLa-IG20 cells when compared to control cells (FIG. 15B). A similar increase was observed in the DR5 DISC from HeLa IG20 cells (FIG. 19B). Increased FADD recruitment to the DISC associated was observed with both DR4 and DR5 in HeLa IG20 cells relative to control cells. Although similar amounts of DR5 were immunoprecipitated from both cell types, there was considerable increase in the DISC components from HeLa-IG20 cells (FIG. 19B). In fact, the level of immunoprecipitated DR4 is lower in HeLa IG20 samples compared to control cells and yet it showed higher levels of caspase-8 recruitment (FIG. 19A).

[000128] IG20 can render cells more susceptible to TRAIL induced apoptosis primarily by increasing the recruitment of FADD and caspase-8 to the DISC that results in enhanced activation of caspase-8 and caspase-3. These observations are consistent with the results obtained using caspase inhibitors and DN-FADD and further support the notion that IG20 is modulating the TRAIL induced apoptosis by increasing DISC formation.

[000129] Apoptosis is characterized by universal activation of caspases. IG20 increased TRAIL induced caspase activation substantially relative to the levels seen in control cells. This was further confirmed by increased mitochondrial depolarization and increased chromatin condensation, which are hallmarks of apoptosis (FIG. 13). Cell surface expression of the DRs and DcRs were at comparable levels in HeLa IG20 and

control cells. Similarly, there was no significant difference in the turnover of the surface receptors (FIG. 14). Therefore, the enhanced susceptibility of HeLa IG20 could not be accounted for by the differential surface expression or turnover of DRs or DcRs.

000130] A considerable increase in not only caspase-8 and -10, but also in caspase-9, which is primarily activated by the mitochondrial pathway, was seen in HeLa IG20 cells (FIG. 15A). Fluorescence-conjugated peptide inhibitors were used to detect activation of specific caspases. The caspase-8 activation was corroborated, by detecting its cleaved p10 fragment, using a specific antibody (FIG. 15B). Downstream effector caspases can be activated either by caspase-8 directly (Type I response) or indirectly through Bid cleavage, resulting in the activation of caspase-9 through the mitochondrial pathway (Type II response), or both. Activation of the mitochondrial pathway, although first described in CD95 mediated signaling, is now implicated in TRAIL induced apoptosis where the susceptibility of certain cancer cells to apoptosis is dependent upon the presence of smac/DIABLO and Bax. Similarly, caspase-10 can participate along with caspase-8 in DR4 and DR5 signaling pathway. One of the known consequences of activation of initiator caspases, like caspases-8, -10 and -9, is that they all can activate the downstream effector caspase-3. An increase in caspase-3 was evident in HeLa IG20 cells.

[000131] Due to its broad effect, p35 can protect against death receptor as well as stress-induced mitochondria mediated apoptosis. Expression of p35 in HeLa cells with and without IG20 totally blocked TRAIL induced apoptosis, most likely by inhibiting relevant caspases. On the other hand, CrmA can protect cells from undergoing TNF- α and CD95 ligand induced apoptosis by primarily inhibiting caspase-8. Although HeLa IG20 cells showed enhanced activation of caspases-8, -9 and -10, CrmA inhibited TRAIL induced apoptosis almost completely (FIG. 16) and strongly supported the notion that IG20 can enhance TRAIL induced apoptosis primarily through enhanced activation of caspase-8.

[000132] IG20 pro-apoptotic splice variants can enhance TNF- α induced apoptosis through increased activation of caspase-8. IG20 has a similar effect on TRAIL induced caspase-8 activation. Collectively, these studies show that IG20, like FADD and caspase-8, is involved in the signaling pathway of more than one member of the TNF super family.

[000133] FADD is necessary for caspase-8 recruitment to the TRAIL DISC. Therefore, a DN-FADD was used to prevent FADD, and subsequent caspase-8 recruitment and showed that it could suppress TRAIL induced apoptosis in HeLa-IG20 cells. Similarly, FADD cannot directly interact with IG20, and yet a total abrogation of apoptosis in DN-FADD transfected cells was observed (FIG. 16). These observations raised the possibility that IG20 could be acting upstream of FADD perhaps through direct interactions with the DRs. Results from co-transfection of fluorescently tagged DR4 and IG20 showed co-localization of these two proteins in HeLa cells. Moreover, co-immunoprecipitation of death receptors and IG20 showed that they interact with each other.

[000134] CD95L and TRAIL induced signaling results in DISC formation characterized by the recruitment of FADD and caspase-8. Subsequent to TRAIL treatment, there was not only an increased recruitment of FADD and caspase-8 to the DISC in HeLa IG20 cells but also an increase in cleaved caspase-8. Furthermore, a significant increase in FADD recruitment to the DISC was found earlier after TRAIL treatment in HeLa IG20 cells, relative to the levels seen in the control cells. The levels or presence of caspase-10, were not tested since it has been shown that even though caspase-10 is recruited to DR4 and DR5, it does not functionally substitute for caspase-8. Moreover, near complete inhibition of apoptosis in the presence of CrmA also indicated that caspase-8 was sufficient for TRAIL induced apoptosis of both HeLa IG20 and control cells.

[000135] IG20 is a pro-apoptotic protein that can interact with DR4 and DR5 and significantly enhance TRAIL induced apoptosis by facilitating DISC formation with increased recruitment of FADD and caspase-8.

[000136] **Example 3: IG20, a MADD splice variant, increases cell susceptibility to γ -irradiation and induces soluble mediators that suppress tumor cell growth**

[000137] HeLa cells were stably transfected with either a vector control, DENN-SV and IG20. Equal numbers of cells were treated to 6, 8, 10 and 12 Grays of γ -irradiation, plated and then allowed to grow for 2 weeks, after which they were stained with crystal violet. Transfected HeLa cells began responding differently at 8 Grays of irradiation and this difference increased with the doses. A representative experiment (FIG. 20) demonstrates the effect of 12 Grays of irradiation on each of the transfected

cell lines. HeLa DENN-SV cells were highly resistant, while HeLa IG20 cells were more susceptible, to the effects of γ -irradiation as compared to control cells.

[000138] To determine whether the effects of γ -irradiation on HeLa IG20 growth was primarily due to enhanced susceptibility or due to reduced cell proliferation. IG20 and control cells were exposed to different amounts of γ -irradiation and then the percentage of cells undergoing apoptosis was assayed by measuring active caspase 3. As shown in FIG. 20C, there was a relatively small difference between the degrees of apoptosis seen, after γ -irradiation, in HeLa IG20 cells, as compared to controls (approximately 10%). This indicated that the reduced number of HeLa IG20 colonies (FIG. 20B), relative to controls, cannot be accounted for by apoptosis alone. Therefore, the effects of IG20 and DENN-SV on the growth properties of HeLa cells were evaluated.

[000139] Equal numbers of HeLa control, IG20 and DENN-SV cells were plated and then counted every other day for a total of 9 days. As seen in FIG. 21A, there was a significant difference in the numbers of cells over the nine day period. The HeLa DENN-SV cell numbers were dramatically increased, while the number of HeLa IG20 cells was lower relative to controls.

[000140] To confirm that the differences in cell numbers seen in FIG. 21A, were due to differences in their growth rate and not due to differences in cell death, to determine the relative rate of cell division, the CFSE dye was used to stain the intracellular protein content of these cells. As the cells divide, the CFSE intensity decreases by half, which can then be assayed for by flow cytometry. As can be seen in FIG. 21B, there is a reduced dilution of CFSE in the HeLa IG20 cells as compared to the control and HeLa DENN-SV cells. This indicated a lag in the division time of the HeLa IG20 cells compared to the other two cells and demonstrated that the differences in the numbers of cells seen in the growth curve is due, to a significant extent, to differences in the rate of cell division. These results show that IG20 renders cells more susceptible to the apoptotic effects of γ -irradiation and slows the rate of cell division.

[000141] Interestingly, the growth curve seen in FIG. 21A demonstrates a biphasic mode. Early on, all three cells demonstrated similar growth but subsequently they showed divergence. This suggested that the effects on cell proliferation might depend on the accumulation of a critical factor(s) in the culture that either promotes (as in DENN-SV cells) or inhibits (as in IG20 cells) cell growth. To test this, trans well chamber experiments were carried out, which indicated that conditioned medium

from IG20 transfected cells could suppress the growth of control as well as IG20 or DENN-SV transfected cells. However, conditioned media from the other two cells had no discernible effect on cell growth. This indicated that a soluble factor(s) secreted by HeLa IG20 cells may be responsible for slowing cell growth and that it could work in trans.

[000142] To confirm the above results, control, HeLa IG20 and HeLa DENN-SV cells were grown for 7 days to assess their growth. In parallel experiments, the culture medium of HeLa DENN-SV cells was replaced daily starting day 4 with corresponding conditioned medium (CM) from HeLa IG20 cell culture or CM from DENN-SV was used to replenish HeLa IG20 cells. The cells were allowed to grow for 3 more days (for a total of 7 days). Results showed that untreated HeLa IG20 and HeLa DENN-SV cells had half and twice the number of cells seen in controls respectively (FIG. 22A). HeLa DENN-SV cells treated with CM from HeLa IG20 cultures grew as slow as the HeLa IG20 cells. Replenishing HeLa IG20 cells with CM from HeLa DENN-SV cultures rescued cell numbers. The reduction in the number of cells was either due to cell death or differences in cell proliferation. To determine relative differences in the rate of cell replication, the cells were stained with CFSE and tested for dye dilution after treatment with different CM media. FIG. 22B shows the cell division rates normally seen in control, DENN-SV and IG20 cells. FIG. 22C shows the effects of reciprocal exchange of CM between HeLa DENN-SV cells and HeLa IG20 cells. The addition of HeLa IG20 CM to HeLa DENN-SV cells reduced their rate of cell division (FIG. 22C) while replacement of HeLa IG20 medium with CM from HeLa DENN-SV alleviated the reduction in cell division.

[000143] HeLa IG20 cells produce soluble factor(s) that could suppress its own growth as well as that of other HeLa cells. To see whether this effect could be seen when cells unrelated to HeLa cells were exposed to the CM from HeLa IG20 cells, the CM from confluent HeLa IG20 cells, but not from control or DENN-SV cells profoundly suppressed the cell growth of PA-1 ovarian cancer cells (FIG. 23A). This effect was again due to a reduction in cell growth and not enhanced apoptosis since these cells did not dilute their CFSE stain to the same extent as cells that were treated with CM from control or HeLa DENN-SV cells (FIG. 23B I, II, III).

[000144] FIG. 24 shows that mitotic bodies, as revealed by nuclear DAPI staining, are lacking in PA-1 cells treated with CM from HeLa IG20 cells. A total lack of PA-1 cell division was also corroborated using mpm2, a mitosis specific antibody. The PA-1

cells left un-treated or treated with CM from control HeLa, HeLa DENN-SV or HeLa IG20 cells for 24 hours were found to have 2.2%, 2.9%, 2.9% and 0% cells staining positive for mpm2, respectively. Cell cycle analysis (FIG. 25) showed that the PA-1 cells treated with CM from HeLa IG20 cells were growth arrested in the G1-G0 stage of the cell cycle.

[000145] To determine the identity of the soluble factor(s) produced by HeLa IG20 cells, culture supernatants from control and HeLa IG20 cells were subject to a multiplex assay to detect the presence of a variety of cytokines. There was a mild upregulation of many of the cytokines in the supernatant of HeLa IG20 cells as compared to the control cells, but IL-6 was significantly up regulated (~20 fold). The levels of IL-6 in CM from all three cell cultures and found a marked increase in only CM from HeLa IG20 cells and not from the other two. Although, FIG. 26A shows the amounts of IL-6 produced from cells grown in serum free media, the results are the same from cells grown in serum containing media. Because one of the more important transcription factors involved in the regulation of IL-6 is NF- κ B, the basal levels of NF- κ B were tested. Entirely consistent with the increased levels of IL-6 production, HeLa IG20 cells showed a significantly higher basal level of NF- κ B activity relative to the other two cells (FIG. 26B).

[000146] To determine the potential contribution of IL-6 to the growth inhibiting property of the CM from HeLa IG20 cell culture, PA-1 cell growth was assayed in the presence of CM from HeLa IG20, HeLa DENN-SV and control cells treated with and without an IL-6 blocking antibody. FIG. 27 demonstrates that the PA-1 cell growth inhibition mediated by the CM from HeLa IG20 cells can be reversed by the addition of an IL-6 neutralizing antibody. However, the anti-IL-6 antibody had no effect on the growth patterns of the PA-1 cells grown in the presence or absence of CM from other cells. This demonstrated that the IL-6 was, at least in part, responsible for the cell growth inhibitory effects of the CM from HeLa IG20 cells.

[000147] The effects of IG20 over-expression on the susceptibility of HeLa cells to TRAIL and γ -radiation induced cell death were determined. HeLa cells either transfected with a control vector or a vector containing IG20 were exposed to γ -radiation and allowed to grow. Twenty-four hours later, these cells were treated with TRAIL for 3 hours and subjected to flow cytometry in order to determine the levels of caspase-3 as an indicator of apoptosis. These results showed that IG20 HeLa cells were more susceptible to treatment with either γ -radiation or TRAIL alone relative to

controls (FIG. 28). However, this difference was more profound when the cells were exposed to a combined treatment with γ -radiation and TRAIL (FIG. 28).

[000148] Of the four different splice variants encoded by the IG20 gene, only IG20 and DENN-SV show effects on cell proliferation and induced death (FIG 20). DENN-SV is highly expressed in tumor tissues relative normal tissues, and its over-expression in various cell lines renders them resistant to TNF α , TRAIL, etoposide and vinblastine induced apoptosis and enhances their proliferation. In contrast, IG20 renders cells susceptible to the above treatments and suppresses cell proliferation.

[000149] Along with chemotherapy, radiation therapy remains one of the most important modalities of treatment for cancer. Therefore, to see if over-expression of the DENN-SV and IG20 in HeLa cells could affect their ability to survive and grow after γ -irradiation, 12 Grays of γ -irradiation adversely affected both HeLa control and HeLa IG20 outgrowth. However, DENN-SV transfected HeLa cells readily recovered from the treatment and showed considerable growth. There was a difference in the recovery of HeLa IG20 relative to control HeLa cells, with the HeLa IG20 cells showing the least recovery from the effects of irradiation.

[000150] Although HeLa IG20 cells were more susceptible to γ -irradiation induced apoptosis, it alone was not sufficient to explain the reduction in their outgrowth following γ -irradiation. Upon closer examination of the growth characteristics, it appeared that the HeLa DENN-SV and HeLa IG20 cells grew faster and slower respectively than HeLa control cells (FIG. 21). The HeLa IG20 cell growth curve demonstrated a biphasic pattern where the growth was very similar to that of HeLa controls and HeLa IG20 cells up to day 5, and then abruptly changed with HeLa IG20 cells growing considerably slower. This suggested that a minimum concentration of a critical factor or signal might be required for the growth suppressive effect. Trans well experiments and reciprocal exchange of CM from IG20 and DENN-SV transfected cells showed that a critical factor(s) was present in the culture supernatant of HeLa IG20 cells, and that it could affect the growth of control and HeLa DENN-SV cells. Moreover, it also suggested that the growth inhibitory property of the CM from HeLa IG20 cells could dominate the growth potentiating properties of DENN-SV (FIG. 22C).

[000151] The CM from HeLa IG20 cells had a profound effect on the ovarian cancer cell PA-1, and completely stopped its growth as determined by cell proliferation (FIG. 23A), dilution of CFSE (FIG. 24B), staining for mitotic bodies (FIG. 25) and cell

cycle analysis (FIG. 25B). This clearly demonstrated that the soluble factor present in HeLaIG20 culture supernatant could not only suppress HeLa cell growth but also the growth of PA-1 ovarian cancer cells. Moreover, accumulation of PA-1 cells in the G0-G1 phase of the cell cycle suggests that the CM either induced PA-1 cells to undergo senescence (G0) or cell cycle arrest at the G1 checkpoint.

[000152] When supernatants from HeLa IG20 cells and control cells were compared for the amounts of several cytokines, some increase in the amounts of most of the cytokines tested were observed, however, there was a profound increase in the amount of IL-6. This was further confirmed by ELISA results that showed elevated levels of IL-6 in the CM from HeLa IG20 cells but not from the others. The importance of IL-6 in suppressing the growth of PA-1 cells was further established when a considerable reversal of the effect was noted in the presence of a neutralizing IL-6 antibody (FIG. 27). The antibody did not completely reverse the growth suppressive effects of the HeLa IG20 CM and suggested that IL-6 might be one of the factors that can cause growth suppression.

[000153] Indeed, it is not uncommon to see the production of IL-6 by tumor tissues and cancer cell lines, including cervical and ovarian cancers. However, the effect of IL-6 on cancer tissues and cell lines is highly dependent on the tissue type and the cells involved, and sometimes the effects may vary even within the same tissue. For example, IL-6 may enhance or deter cell growth depending upon the ovarian cancer cell line being tested. As disclosed herein, IL-6 inhibited the growth of PA-1 ovarian cancer cells in a manner consistent with blocking cell cycle progression at the G1-G0 stage. Earlier studies have shown that upon IL-6 treatment, early stage melanoma cell lines, human prostate cell line LNCaP and leukemic myeloblastic cells are also growth arrested at the G1-G0 stage of the cell cycle. The mechanism by which IL-6 induces growth arrest and/or differentiation is unclear but may involve the induction of CDK inhibitors.

[000154] IL-6 production can also play a pivotal role in cancer progression. In an earlier study it was observed that IL-6 produced by skin fibroblasts could inhibit the growth of early melanomas but not advanced stage melanomas. This was not due to differences in the levels of expression of either the IL-6 receptor or the IL-6 transducer (gp130). Interestingly, the melanoma cells themselves secreted IL-6. Further studies then showed that IL-6 undergoes transition from being a paracrine growth inhibitor to an autocrine stimulator during human melanoma progression.

[000155] IG20 can enhance radiation-induced apoptosis (FIG. 20C). This coupled with a previous observations that IG20 can enhance TRAIL and TNF α induced apoptosis suggest a convergence of the extrinsic (i.e. TNF α and TRAIL) and the intrinsic apoptotic pathways (i.e. γ -irradiation). Induction of the extrinsic pathway through TNF α and TRAIL binding to their cognate receptors activates caspase 8 and subsequently the effector caspase 3. When the cells are stressed, the intrinsic pathway is initiated through the mitochondria resulting in the activation of caspase 9 and then caspase 3. Results show that although over-expression of IG20 results in constitutive upregulation of NF- κ B, upon intrinsic or extrinsic death stimulus the ability of IG20 to enhance caspase activity predominates.

[000156] The combined effects of TRAIL and etoposide or CDDP (chemotherapeutic DNA damaging agent) could cooperatively induce apoptosis of glioma cells *in vitro* and reduce tumor loads in nude mice *in vivo*.

[000157] Significant implications for cancer therapy are associated with the invention because DENN-SV is highly expressed in tumors with little or no expression of IG20. Further, over-expression of IG20 can render PA-1 cells more susceptible to TRAIL induced apoptosis. HeLa cells normally express both the antiapoptotic (DENN-SV) and the pro-apoptotic (IG20) variants. The efficacy of α -irradiation induced cell death is enhanced by IG20 over-expression. Exposure to both TRAIL and α -irradiation can work cooperatively and enhance apoptosis even more significantly (FIG. 28).

[000158] Nude mice injected with 1×10^6 PA-1 cells sub-cutaneously, develop tumor growth as shown in FIG. 29 (top panels), whereas nude mice injected with 1×10^6 PA-1-IG20 cells do not develop tumor growth after 11 weeks (FIG. 29, bottom panels).

[000159] IG20 can render cells more susceptible to apoptosis and suppress cell growth. This raises the possibility of using IG20 to render cells that are otherwise resistant to become more susceptible to various modalities of cancer therapy.

MATERIALS AND METHODS

[000160] *RT-PCR Using RNA From Human Tissues*

[000161] Human tissue samples were provided by the Cooperative Human Tissue Network (CHTN), which is funded by the National Cancer Institute. Highly pure intact full-length poly-A⁺mRNAs were directly isolated from various tissues using μ MACS mRNA Isolation Kit (Miltenyi Biotec Inc., Auburn, CA) according to the manufacturer's protocol. Briefly, tissues were minced, lysed, mixed with the MicroBeads conjugated to Oligo (dT) and then loaded onto the μ MACS magnetic

columns. The columns were washed and the bound mRNAs eluted with hot (65°C) RNase-free water. Fifty ng mRNA from each sample was used in SuperScript-One-Step RT-PCR System (Life Technologies, Rockville, MD). Depending on the length of the product, RT-PCR protocols differed only in the extension time (at 72°C) and the primers used; otherwise, protocols were identical. A first incubation at 50°C for 30 minutes was followed by incubation at 94°C for 2 minutes. Subsequent 30 cycles of PCR were carried out at 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for variable time periods (as described herein), followed by a final incubation at 72°C for 7 minutes. For amplifying exons 13L and 16, F-1 and B-1 primer pair (5' CGG GAC TCTGAC TCC GAA CCT AC 3' and 5' GCG GTT CAG CTT GCT CAG GAC 3', respectively) was used, with 1 minute extension time. For amplifying exon 21, F3453 and B3648 primer pair (5' AAG TGC CAC AGG AAA GGG TC 3' and 5' TGC GCT GATCTG GGA CTT TT 3', respectively) was used, with 30 seconds extension time. For amplifying exon 26, F3944 and B4123 primer pair (5' AGC CAT GCA TAA AGG AGAAG 3' and 5' GGT CCC ATA AAG TAG AAC GC 3', respectively) was used, with 30 seconds extension time. For amplifying exon 34, F4824 and B5092 primer pair (5' CTGCAG GTG ACC CTG GAA GGG ATC 3' and 5' TGT ACC CGG GTC AGC TAG AGACAG GCC 3', respectively) was used, with 30 seconds extension time. All primers were used at 10 µM each. The resultant cDNAs were separated on 5% polyacrylamide gels (PAGE) and compared to molecular size markers to determine the product size.

[000162] *Sequencing of RT-PCR Products*

[000163] To sequence the PCR products, 10 µl of cDNA from representative RT-PCR products were run on PAGE until the desired fragments were clearly separated. Then, bands corresponding to the expected size of a given variant were excised, purified and cloned into pGEM-Teasy vector (Promega, Madison, WI), and used to transform *E. coli* DH5α. Clones containing the desired fragments were identified by restriction analysis and sequenced using the corresponding primers described herein.

[000164] *Cloning of IG20 Splice Variants Into Mammalian Expression Vectors*

[000165] IG20, MADD and DENN-SV were each separately cloned into the multiple cloning sites (MCS) of pBKRSV (Stratagene, La Jolla, CA), and pCDNA 3.1 His vector (Invitrogen, Carlsbad, CA) as described by Al-Zoubi *et al.*, (2001). The remaining four IG20 splice variants (i.e., IG20-FL, KIAA0358, IG20-SV2, and IG20-SV4) were first cloned into pBKRSV and then into pCDNA 3.1 His vector. IG20

cloned into 21pBKRSV as a backbone was used, as described herein. KIAA0358 (clone number hh00017 inserted at the SalI-NotI site of the pBluescript IISK+ (pBSSK) vector) was kindly provided by Kazusa DNA Research Institute (Chiba, Japan). Similarly, IG20-SV4 was cloned into pBSSKII at the SalI-NotI site. Both KIAA0358 and IG20-SV4 were excised out of pBSSKII and cloned into pBKRSV at the SalI and NotI sites. To clone IG20-FL into pBKRSV, both pBSSK-KIAA0358 and pBKRSV-IG20 were digested with AatII and KpnI that flank the region containing exons 21 and 26 (FIG. 2). The AatII-KpnI fragment of KIAA0358 that contains unspliced exons 21 and 26 was used to replace the corresponding fragment in pBKRSV-IG20 that lacks these exons. To clone IG20-SV2 into pBKRSV, both DENN-SV and pBKRSV-IG20 were digested with AatII, which cuts at two sites on IG20 (and DENN-SV) that flank exons 13L and 16. Digestion of pBKRSVIG20 with AatII produced two fragments of about 1 and 8.3 kb, and digestion of DENNSV produced two fragments of about 1 and 5 kb. The 1 kb fragments from both were further digested with Esp31 that cuts between exons 13L and 16. The AatII-Esp31 fragment from DENN-SV that spans exon 13L (where exon 13L is spliced into 13S) was used to replace the corresponding fragment in pBKRSV-IG20 (where exon 13L is unspliced). Restriction analyses and sequencing confirmed the appropriate cloning of each of the above cDNAs into pBKRSV. To construct tagged cDNAs, we used pCDNA 3.1 His-IG20 as a backbone. IG20-FL, IG20-SV2, IG20-SV4, and KIAA0358 were cloned into pCDNA 3.1 His-IG20 at ClaI site at 279 nucleotides downstream of IG20 ATG start codon and NotI site at the c-terminal of IG20. The correct clones were identified by restriction analyses using NotI and ClaI, and then with AatII, and by sequencing.

[000166] *Transfection of mammalian Cells with cDNAs Encoding Different IG20 Splice Variants*

[000167] Control pCDNA 3.1 His vector, or vector containing various cDNAs, were used for transfecting HeLa, 293T and PA-1 cell lines. Cells were transfected using Super-Fect Transfection Reagent (Qiagen) according to previously published protocols (Al-Zoubi *et al.*, 2001). To select for permanently transfected cells, growth medium was replaced at 24 hours post-transfection, and then once every three days for 21 days, with fresh medium containing 400 µg/ml G418. Expression of transfected cDNAs was then confirmed by immunoblotting as described herein.

[000168] *Immunoprecipitation of IG20 Splice Variants*

[000169] Permanently transfected human embryonic kidney (293T) cells were plated in 150 cm² dishes at 8X10⁶ cells/dish and grown overnight. Next day, cells were harvested by trypsinization and then counted; equal numbers of cells from all samples were used. Further processing of cells and cell lysates was carried out at 4°C. Cells were washed once in ice-cold PBS and were incubated in lysis buffer T (20 mM Tris-Cl, pH 7.5, 1% TritonX-100, 137 mM NaCl, 25 mM β-glycerophosphate, 2 mM EDTA, 1 mM Na₂VO₄, 2 mM sodium pyrophosphate, 10 % (v/v) glycerol, 10 μg/ml leupeptin, and 2 mM phenylmethylsulfonyl fluoride) for 1 hour. Lysates were subjected to centrifugation at 13000 rpm for 30 minutes, supernatants were transferred to other tubes and total protein concentration was determined. Equal amounts of total protein from each sample were used in subsequent immunoprecipitations. Samples were pre-cleared by incubation with 5 μl/sample of normal rabbit sera for 30 minutes followed by addition of 25 μl protein A/G PLUS-Agarose (Santa Cruz Biotechnology, Santa Cruz, CA) and further incubation for 30 minutes. Samples were then centrifuged at 13000 rpm for 1 minute, and the supernatants were transferred into new tubes and incubated at 4°C overnight with 5 μl of a mixture of anti-IG20 N, C and M antibodies. These antibodies were generated against three different peptides derived from the N-terminus (N) C-terminus (C) and the middle part (M) of the protein as described by Al-Zoubi *et al.* (2001). To detect specific IG20 variants, the above immunoprecipitated samples were separated and then transferred onto nitrocellulose membrane and detected using anti-His monoclonal antibodies (Clonotech).

[000170] *TNFα Treatment of Cells*

[000171] Cells were plated in 6-well plates at 1.2 X 10⁵ in growth medium. Twenty four hours later, cells were either untreated or treated with 10 ng/ml TNF-α and 10 μg/ml cyclohexamide (CHX) for 6 hours. To assess the effects of TNFα and CHX treatment, cells were either stained with 100 nM tetramethylrhodamine ethyl ester (TMRE) (Molecular Probes, Eugene, OR) for 10 minutes, harvested by trypsinization, washed once with ice-cold PBS and then subjected to FACS analysis, or were stained with either trypan blue and evaluated for viability using a light microscope, or with 1 μg/ml Hoechst 33342 (Sigma) for 10 minutes and evaluated for chromatin condensation *in situ* using a Diaphot 200 inverted microscope with an epi-fluorescence attachment (Nikon, Melville, NY).

[000172] *Drug treatment of Cells*

[000173] Cells were plated (10^5 cells/well) the day before treatment into 6 well plates. Cells were treated with etoposide for 24 hours or vinblastine for 1 hour at indicated concentrations. After treatment, cells were washed 3 times with PBS and then replenished with fresh media and incubated at 37° C. Two weeks later, cells were fixed in ice-cold methanol and stained with crystal violet for visualization.

[000174] *TRAIL treatment of cells*

[000175] PA-1 cells were plated in 6 well dishes (5×10^5 cells/well). Next day, cells were treated *in situ* with 50 ng/ml TRAIL (Peprotech, Rocky Hill, NJ) for 3 hours with or without 50 μ Mz-VAD (30 minute pre-incubation). Cells were then assayed for levels of active caspase 3.

[000176] *Active caspase 3 assay*

[000177] Cells were harvested, washed once with PBS and then fixed in Cytofix/Cytoperm solution and washed with Perm/Wash buffer as suggested by the manufacturer (Pharmingen, San Diego, CA). Cells were then stained with PE-conjugated rabbit anti-active caspase 3 antibody according to the manufacturer's protocol (Pharmingen). Cells were then subjected to FACS analysis to determine percentage of cells with active caspase 3.

[000178] *Proliferation and Colony formation in soft agar*

[000179] To measure cell proliferation, cells were plated in triplicates at 1×10^5 Cells /100 mm² plate, and then were harvested and counted on days 1, 3 and 5 after plating. To assess the ability of cells to form colonies in soft agar, 1.4 % Agarose in water was mixed with 2X DMEM (20% FCS, 2X pen/strep) to create the bottom layer; 1 ml of this was used to line the bottom of each well (6 well dishes). Variable numbers of cells diluted in 1 ml of DMEM (supplemented with 10% FCS, pen/strep) were mixed with 1 ml of 0.7% agarose in DMEM (liquid form) and used to form the top layer (final 0.35% Agarose in DMEM 10%FCS, penicillin/streptomycin). Colony formation was observed under a microscope.

000180] *CFDA staining of cells*

000181] 1×10^5 Cells/100 mm² plate were stained with 2 μ M CFDA (Molecular Probes, Eugene, OR) *in situ* in 5 ml PBS/100mm² for 10 minutes at 37°C. Cells were then washed 3 times and replenished with new media. Cells were harvested 5 days later and analyzed by FACS.

[000182] *Hoechst Staining*

[000183] Cells were stained *in situ* with 1 µg/ml of Hoechst 33342 (Sigma, St. Louis, MO) in DMEM for 10 minutes at 37°C. Chromatin condensation was then visualized *in situ* using a Diaphot 200 inverted microscope with an epifluorescence attachment (Nikon, Inc., Melville, NY). 10 different fields were randomly chosen to determine the average number of cells with condensed chromatin (apoptotic) as compared to live cells.

[000184] *Luciferase Assay for NFκB activation*

[000185] Measurement of NFκB activation was performed using the Dual-Luciferase Assay System (Promega, Madison, WI) according to manufacturer's protocol. Briefly, cells were plated in 12 well dishes (5X10⁵ PA-1 cells/plate) and 18-24 hours later were co-transfected with 0.01 µg/well of NFκB firefly luciferase reporter construct and 0.001 µg/well of Renillaluciferase control vector pRL-SV40. Cells were allowed to recover for 24 hours and then replenished with serum free medium. Next day, cells were left untreated or treated for 5 hours with TNFα or TRAIL. Subsequently, they were washed and lysed *in situ* for 30 minutes with gentle agitation using the manufacturer's lysis buffer. 20 µL of each lysate was then used to test for levels of firefly luciferase activity and normalized with the level of Renilla luciferase activity.

[000186] *Transfection of cells with DN-IκBα and CrmA*

[000187] Cells were plated in 6-well plates at 1.5X10⁵/well in growth media. Twenty-four hours later, cells were transfected with either a cDNA encoding farnesylated GFP (GFP-f) alone, or co-transfected with either an empty vector, or a vector containing cDNA encoding either CrmA or DN-IκBα, at a 1:5 ratio. At 24 hours post-transfection, cells were either untreated or treated with TNFα and cyclohexamide for 6 hours, as described herein. Then, cells were stained with TMRE and subjected to FACS analysis; only GFP-f-gated cells were included in the analysis.

[000188] *RT-PCR of TNFα-Resistant HeLa Cells*

[000189] To separate cells that were undergoing apoptosis, or resistant to apoptosis upon TNFα treatment, the Annexin V microbeads (Miltenyi Biotec, Inc.) were used according to manufacturer's protocol. Annexin V is a phospholipid-binding protein that recognizes phosphatidylserine on the surface of apoptotic cells. Briefly, cells were plated and treated with TNFα and CHX for 6 hours as described herein, washed once with PBS to remove dead cells and debris, collected, passed through 30 µM filter,

and incubated with Annexin Vmicrobeads for 15 minutes at 6-12 °C, and then washed once and resuspended in 500 µl buffer. Cells were then passed through a magnetic column. Flow through included non-apoptotic, TNF α -resistant cells, whereas cells bound to the column represented apoptotic cells. Columns were washed three times with buffer, removed from magnet and cells bound to the matrix were eluted. Untreated control, TNF α -resistant, and apoptotic cells were then used for isolation of Poly-A+ mRNA using the μ MACS mRNA Isolation Kit (Miltenyi Biotec), or were used for TMRE staining to determine percentage of apoptotic cells, as described herein.

[000190] **Construction of plasmids** - A cDNA encoding IG20 pro-apoptotic splice variant (GenBank Accession Code-AF440101, termed IG20 was cloned in-frame into pcDNA3.1/NT/GFP/TOPO vector (Invitrogen, Carlsbad, CA) using the TA cloning site from the pBKRSV clone described by Al-Zoubi *et al.*, (2001). The His-tagged IG20 construct has been described herein. IG20 was also sub-cloned into Bgl II and Apa I sites of the EYFP-C1 vector (Clontech, Palo Alto, CA). The IG20 construct was made by specific PCR amplification of a 748-residue fragment (amino acid 628 to 1376) from the full length IG20. This PCR amplified product was directly ligated into the TA cloning site of pcDNA3.1/NT/GFP/TOPO vector. The DR4- Flag construct, a gift from Vishva M. Dixit (Genentech, South San Francisco, CA), was used to sub clone DR4 into the Bgl II and EcoR I sites of ECFP-N1 vector (Clontech). The DR5-Myc was a gift from W. S. El-Deiry (University of Pennsylvania, Philadelphia, PA) and was used to clone the DR5 construct into the Bgl II and Eco RI sites of ECFP-N1 vector.

[000191] **Cell lines** - IG20 tagged with GFP and the pcDNA3.1/NT/GFP/TOPO empty vector (10 µg each) were transfected into HeLa cells using the superfect reagent from Qiagen Inc. Valencia, CA. Three hours post-transfection, cells were washed with 1XPBS and replenished with Dulbecco's Modified Eagle's medium (Gibco Invitrogen Co., Carlsbad, CA) with 10% Fetal Bovine serum, 2mM L-glutamine and antibiotics (penicillin G-100 units/mL and streptomycin-100 µg/mL). All cell lines were cultured at 37 °C in a humidified atmosphere containing 5%CO₂. Stably transfected cells of HeLa IG20 and Vector Control were established by culturing cells in growth medium containing G418 (400 µg/mL) for 3 weeks, with weekly change of the medium and expression was confirmed by immunoprecipitation of IG20-GFP protein.

[000192] Antibodies and other reagents - The anti-IG20 peptide polyclonal antibody, raised against 3 different peptides from the N-terminal, middle and C-terminal region of IG20, has been described by Al-Zoubi *et al.*, (2001). Anti Caspase- 8 antibody (C-15) was a gift from Marcus E. Peter (Ben May Institute of Cancer Research, University of Chicago, Chicago). Anti caspase-8 monoclonal antibody 6B6 was purchased from Cell Signaling Technology Inc, Beverly, MA. PE-conjugated rabbit anti active Caspase-3 antibody and anti- FADD antibodies were obtained from BD PharMingen, San Diego, CA., anti-His antibody was purchased from Clontech PaloAlto, CA, anti-Flag M2 monoclonal from Sigma-Aldrich Corp., St. Louis, MO, USA; anti-DR5 (IMG 120, rabbit polyclonal), anti-DR4 (H-130, rabbit polyclonal) and B-9 (mouse monoclonal) antibodies were obtained from Santa Cruz Biotechnology, Inc., Santa Cruz, CA. TNF- α and Cycloheximide were obtained from Sigma-Aldrich Corp and recombinant human TRAIL was purchased from Peprotech Inc., Rocky Hill, NJ.

[000193] Mitochondrial depolarization and chromatin condensation - 2X10⁵ HeLa IG20 and Vector control cells were plated into a 12-well culture dish and allowed to grow for 48 hours. Duplicate wells were left untreated or treated with 10 ng/mL of TNF- α and 10 μ g/mL of cycloheximide. Equal numbers of cells were left untreated or treated with recombinant TRAIL at 100 ng/mL and both treatments lasted for 5-hours. Cells were assessed for loss of mitochondrial membrane potential by staining with tetramethylrhodamine ethyl ester (100 nm, Molecular Probes, Eugene, OR) for 10 minutes, washed once with ice-cold PBS, collected and subjected to FACS analysis. Cells from parallel samples were stained with 1 μ g/mL Hoechst33342 (Sigma-Aldrich Corp) for 10 minutes and viewed under a Diaphot 200 inverted microscope with an epifluorescence attachment to analyze chromatin condensation.

[000194] Caspase activation - To assess the general activation of caspases, cells were stained with FITC tagged caspase inhibitor Val-Ala-Asp-fluoromethyl ketone (Promega, Madison, WI) for 10 minutes at 37 °C, washed and analyzed by FACS for percentage of FITC positive cells. The initiator caspases were analyzed by using carboxyfluorescein labeled peptide fluoromethylketone inhibitors (FAM-peptide-FMK) directed against active caspase-8, 9 and 10 (APOLOGIX caspase detection kit, Cell Tech Inc., Minneapolis, MN). For testing levels of active caspase-3, cells were fixed and permeabilized using cytofix/cytoperm solution (BD Pharmingen, San Diego, CA) for 30 minutes at 4 °C. Cells were washed with Perm/wash buffer (BD

Pharmingen) and stained for 1 hour in the dark at room temperature with 10 μ L per sample of active-anti-caspase-3 PE conjugated antibody. Cells were collected, washed once, resuspended in Perm/wash buffer and analyzed by FACS for PE positive population. For detecting the caspase-8 cleaved fragment, 1X10⁷ of vector and IG20 transfected HeLa cells were treated with 100 ng/mL of TRAIL for 1 or 3 hours, lysed with RIPA lysis buffer and normalized for protein concentration. The proteins were separated by SDS-PAGE, transferred and probed for the p10 cleaved caspase-8 fragment using the 6B6 antibody.

[000195] Cell surface expression levels of TRAIL receptor - A total of 5 X 10⁵ HeLa control and IG20 cells were collected in enzyme free solution, washed once with PBS containing 0.5% BSA and let stand in the same buffer for 10 minutes at 4 °C. PE-conjugated anti- DR4 (DJR1 clone), anti-DR5 (DJR2-4 clone), anti-DcR1 (DJR3 clone) and anti-DcR2 (DJR4-1 clone) antibodies purchased from eBiosciences, San Diego, CA were used. Each sample was incubated with 20 μ L of specific as well as control mouse IgG antibody per sample for 30 minutes at 4°C. The cells were then washed with 1XPBS and analyzed by FACS using a FACScan (Becton Dickinson, San Jose, CA).

[000196] Brefeldin A treatment - Equal number of control and IG20 HeLa cells were treated with brefeldin A (1 μ g/mL, Sigma- Aldrich Corp.) for the indicated time periods and analyzed by FACS after staining with anti-DR5 antibody (DJR2-4 clone).

[000197] Transfection with dominant negative FADD, CrmA and p35 constructs - Control vector and IG20 stably transfected HeLa cells were plated at 5X10⁵ overnight and the dominant negative FADD, CrmA and p35 constructs were co-transfected (2 μ g each) with farnesylated EGFP at a ratio of 1:5. Equal numbers of wells were co-transfected with an appropriate control vector along with EGFP-F at the same ratio. The transfected cells were left untreated or treated with the TRAIL, or with TNF- α and cycloheximide, for 5 hours and cells were collected and stained for active caspase-3 (anti caspase-3 antibody) and subjected to FACS analysis to detect active caspase-3 staining in GFP- positive cells.

[000198] Co-localization studies - 2X10⁴ HeLa cells plated on chamber slides were co-transfected with the DR4-CFP and IG20-YFP constructs in a ratio of 1:5 (total 5 μ g of DNA). At 12 hours, the cells were treated with 10 μ M of Z-VAD. After 24 hours of transfection, the cells were fixed in 4 % formaldehyde fixative solution, washed with PBS and mounted with cover slips using the vectashield-mounting medium (Vector

Labs, Burlingame, CA). Slides were then imaged on an Olympus 1X70 epifluorescence microscope using the slide book program (Intelligent—ImagingInnovations, Denver, CO) under a 100X oil-immersion objective. The individual channels used were captured in a Z- series on a CCD digital camera.

[000199] Co-immunoprecipitation - Either IG20-His or . IG20-GFP were co-transfected with DR4-Flag in a ratio of 2:1 (a total of 15 µg of DNA) into 0.5X10⁶ 293 T cells using calcium phosphate transfection method. Co-transfections of IG20-His, IG20-GFP were also done with DR5-Myc constructs. Cells were collected and lysed 24 hours after transfection in lysis buffer [20mM Tris/HCl, pH 7.5, 137mM NaCl, 2mM β-glycerophosphate, 2mM EDTA, 1mMNa₃VO₄, 2mM sodium pyrophosphate, 2mM phenylmethylsulfonyl fluoride (PMSF), protease inhibitors cocktail (Roche), 1%Triton X-100 and 10% glycerol] for half hour on ice and then clarified by centrifugation at 12,000 rpm for 30 minutes at 4°C. Cell lysates were immunoprecipitated overnight with either 10 µL/mL of anti-IG20 peptide antibodies, 5 µg/mL of anti-Flag M2 antibodies, 5 µg/mL of Myc antibody (Zymed, South San Francisco, CA) or 5µg/mL of DR5 (IMG 120) . Protein A/G beads were added and samples were conjugated for 2 hours after which beads were washed three times with lysis buffer and boiled in SDS lysis buffer. The eluates were then subjected to SDS-PAGE for subsequent immunoblot analysis.

[000200] Immunoprecipitation and DISC analysis - Control and IG20 HeLa cells (2X10⁷) were collected and left untreated or treated with TRAIL at a concentration of 1 µg/ml in a 37 °C water bath for 10 minutes or 30 minutes. At the end of the treatment, the cells were immediately washed with ice-cold 1X PBS and pelleted. The washed cells were then lysed with 1mL of lysis buffer [30mM Tris/HCl, pH 7.5, 150mM NaCl, 2mM EDTA, 1mMphenylmethylsulfonyl fluoride (PMSF), protease inhibitors cocktail (Roche, Mannheim,Germany), 1%Triton X-100 and 10%glycerol] on ice for 30 minutes and clarified by centrifugation at 12000 rpm for 30 minutes at 4 °C. The supernatants, normalized for protein concentration, were immunoprecipitated with 2 µg of H-130 DR-4 antibody on a roto shaker at 4°C for 4 hours followed by the addition of 25 µL of 50% slurry of Protein A/G (Amersham,Piscataway, NJ) beads for another 2 hours. The beads were washed thrice with lysis buffer and the complex was separated from the beads by boiling it in SDS lysis buffer for 5 minutes. The eluate was subjected to SDS-PAGE using a 12% gel for subsequent Immunoblot analysis.

- [000201] Western blot analysis** - The membranes were blocked with 5% milk (for coimmunoprecipitation assays) or 2% BSA (for DISC analysis) in PBS with 0.5% Tween 20 for one hour and the primary and secondary antibodies were incubated in PBST with 5% milk. The primary antibodies were used at concentrations of 1 µg/mL and the secondary antibodies at a concentration of 1:2000 to 1:10,000. All blots were developed using the ECL plus kit from Amersham following manufacturer's protocol
- [000202] Cell culture** - HeLa and PA-1 cells were grown in DMEM (Gibco BRL, Rockville, MD) supplemented with 10% fetal calf serum, L-glutamine (2mM) and penicillin (100 units/mL)/streptomycin (100 µg/mL). To study the effects of CM, the regular growth medium was replaced with spent medium obtained from different cell cultures as indicated under agiven experiment.
- [000203] γ-irradiation** - HeLa cells were harvested by trypsinization and irradiated in tubes. Cells were then plated at an initial density of 10⁶ cells per p100 plate (PA-1 cells were plated at 2x10⁶ cells per p100 plate) and replenished with fresh culture medium. Cells were allowed to grow for 2 weeks after which they were fixed with ice-cold methanol and stained with crystal violet to observe the outgrowth.
- [000204] TRAIL treatment** - PA-1 cells were plated in 6 well dishes (5x10⁵ cells/plate). Next day cells were treated *in situ* with 50ng/mL of 1mL/well TRAIL (Peprotech, Rocky Hill, NJ) for 3 hours. Cells were then assayed for levels of active caspase 3 as an indicator of apoptosis.
- [000205] Active Caspase 3 assay** - Cells were harvested, washed once with PBS and then fixed in Cytofix/Cytoperm solution and washed with Perm/Wash buffer as suggested by the manufacturer (Pharmingen, San Diego, CA). Cells were then stained with PE-conjugated rabbit antiactive caspase 3 antibodies according to the manufacturer's protocol (Pharmingen, San Diego, CA). The cells were then subjected to FACS analysis to determine the percentage of cells positive for active caspase 3.
- [000206] Staining for mitotic Cells** - PA-1 cells were plated (5x10⁵ /p100). Next day, growth medium was replaced with either fresh medium or conditioned media from control, HeLa IG20 or HeLa DENN-SV cells. Twenty-four hours later, cells were fixed with ice-cold methanol, washed 3 times and stained with DAPI (1 µg/mL, Sigma, St. Louis, MO) in order to visualize mitotic cells.
- [000207] CFSE staining of cells** - Cells were stained with 2µM CFSE (Molecular Probes, Eugene, OR) *in situ* (1 mL PBS/well (12 well plate)) for 10 minutes at 37°C, washed 3 times with PBS and replenished with new media. Cells were harvested 48 or

72 hours later and analyzed using a BD FACSCalibur equipped with CellQuest software. In the case of PA-1 cells, cells were stained in p100 plates as directed above (5×10^5 cells/plate).

000208] Cell cycle staining - PA-1 cells (p100 plate) were harvested and washed in PBS 3 times. Cells were then treated with ice-cold 70% ethanol for 30 minutes on ice and washed with PBS + 2% FCS 2 times and blocked for 10 minutes at room temperature with PBS + 2% FCS. PBS containing PI (40 $\mu\text{g/mL}$, Sigma, St. Louis, MO) and RNase A (20 $\mu\text{g/mL}$, Roche, Indianapolis, IN) was used to resuspend washed cells. Finally the cells were incubated at 37°C for 5 minutes before the analysis using a FACSCalibur. Data were analyzed using Cell Quest and ModFit software.

000209] Mpm2 staining - Cells were harvested, washed once with PBS and then fixed in Cytofix/Cytoperm solution and washed with Perm/Wash buffer as suggested by the manufacturer (PharMingen, San Diego, CA). Cells were blocked with 2% FCS at RT for 15 minutes, and then stained with a mouse anti-mpm2 antibody (provided by Igor Roninson, University of Illinois at Chicago) for 1 hour and then washed 2 X in PBS + 2% FCS. The mpm2 antibody recognizes a phosphorylated epitope (S/T) P found in phosphoproteins such as MAP2, HSP70, cdc25 and DNA topoisomerase II, most of which are phosphorylated at the onset of mitosis. The anti-Mpm2 binding was detected using an anti-mouse PE-conjugated secondary antibody (1/100 dilution: Caltag, Burlingame, CA) for 30 minutes. After 2 washes the cells were analyzed using a FACS calibur.

[000210] Luciferase Assay - Measurement of NF- κ B activation was performed using the Dual-Luciferase Assay System (Promega, Madison, WI) as outlined in the manufacturer's protocol. Briefly, cells were plated in 12 well dishes (5×10^5 PA-1 cells/plate) and 18-24 hours later they were co-transfected with 0.01 μg /well of NF- κ B firefly luciferase reporter construct and 0.001 μg /well renilla luciferase vector pRL-SV40. The constitutively expressing renilla luciferase vector was used to normalize for transfection efficiency. Cells were allowed to recover for 24 hours after which they were fed with serum free culture medium. The next day, cells were washed and lysed *in situ* for 30 minutes with gentle agitation using the manufacturer's lysis buffer. 20 μL of each lysate was then used to test for the levels of firefly luciferase activity and normalized to the levels of renilla luciferase activity. Since firefly and renilla

luciferase fluoresce at different wavelengths, their emissions may be read from the same sample.

[000211] Multiplex assay for cytokines in conditioned media - Multiplex analysis was performed using multiplexed kits purchased from BioSourceInternational (Camarillo, CA) according to the manufacturer's protocol. The assays were performed in 96-well microplate format. A filter-bottom 96-well microplate (Millipore) was blocked for 10 min with PBS/BSA. To generate a standard curve, serial dilutions of appropriate standards provided by the manufacturer were prepared and used. Prepared standards and conditioned media were (50 μ l/well) mixed with 50 μ l of bead mixture in duplicate in the wells of a microtiter plate, and incubated for 1 h at room temperature on shaker. Wells were then washed three times with washing buffer using a vacuum manifold. PE-conjugated secondary antibodies were added to the appropriate wells and incubated for 45 min in the dark with constant shaking. Wells were washed twice, assay buffer was added to each well and samples were analyzed using the Bio-Plex suspension array system, which includes a fluorescence reader and Bio-Plex Manager analytical software (Bio-Rad Laboratories, Hercules, CA). Data analysis was done using five parametric-curve fitting.

[000212] Supernatants from confluent HeLa vector controls and HeLa IG20 cells were tested for the amounts of various cytokines as described in Materials and Methods and concentrations of various cytokines are expressed as pg/mL. ND denotes cytokines not detected.

[000213] IL-6 ELISA - HeLa cells (5×10^5) were plated in p100 petri dishes in serum free or serum containing media. 4 days later, supernatants (conditioned media) were harvested, diluted (1/10) and assayed for the presence of IL-6 cytokine using a human IL-6 ELISA kit (BioSourceInternational, Camarillo, CA) as outlined by the manufacturer.

[000214] IL-6 neutralization - PA-1 cells were plated at 5×10^5 /12 well plate. Next day, media from the PA-1 cells were replaced with 1mL CM from HeLa IG20, HeLa DENN-SV or control cells alone or along with an IL-6 neutralizing antibody (50 μ g/mL, Biosource, Camarillo, CA). 48 hours later, cells were harvested and counted.

DOCUMENTS CITED

The following document is incorporated by reference to the extent it relates to protocols used in this disclosure.

Al-Zoubi AM, Efimova EV, Kaithamana S, Martinez O, El-Azami El-Idrissi M, DoganRE, Prabhakar BS Contrasting Effects of IG20 and Its Isoforms, MADD and DENN-SV, on Tumor Necrosis Factor α -induced Apoptosis and Activation of Caspase 8 and -3 *J.Biol. Chem.* 276 (50): 47202-47211, 2001.

CLAIMS:

- [C1]** Use of IG20 or at least one of its splice variants or a fragment thereof to regulate cell death or cell replication.
- [C2]** The use of claim 1, wherein IG20 or at least one of its splice variants is expressed to a higher than normal level.
- [C3]** The use of claim 1, wherein IG20 or at least one of its splice variants or a fragment thereof is used to regulate tumor cell death or replication.
- [C4]** The use of claim 1, wherein IG20 or at least one of its splice variants or a fragment thereof makes cells more sensitive to induced cell death.
- [C5]** The use of claim 1, wherein cell death is induced by radiation.
- [C6]** The use of claim 1, wherein cell death is induced by chemotherapy.
- [C7]** The use of claim 3, wherein the tumor cells are cancer cells.
- [C8]** Use of DENN-SV or at least one of its splice variants or a fragment thereof to regulate cell death or cell replication.
- [C9]** Use of an anti-sense molecule of DENN-SV or a fragment thereof to promote cell death or suppress cell replication.
- [C10]** Use of Si RNA of DENN-SV or a fragment thereof to promote cell death or suppress cell replication.
- [C11]** The use of claim 8, wherein DENN-SV or at least one of its splice variants or a fragment thereof is used to promote growth of cells or to maintain cells alive.
- [C12]** The use of claim 8, wherein the cell is selected from the group of primary cells consisting of insulin producing cells, neuronal cells, and stem cells.
- [C13]** The use of claim 8, wherein cell replication is suppressed in tumor cells.
- [C14]** The use of claim 1, wherein cell death is induced by a ligand that binds to a death receptor.
- [C15]** The use of claim 14, wherein the death receptor is selected from the group consisting of FAS-ligand, TNF-alpha, TRAIL, or anti-receptor antibodies.
- [C16]** Use of an antibody of IG20 or DENN-SV or at least one of its splice variants or a fragment thereof to regulate cell death or cell replication.
- [C17]** A method to modulate levels of IG20 or DENN-SV to regulate cell death or cell proliferation, the method comprising:

- (a) providing a molecule to regulate endogenous levels of IG20 or at least one of its splice variants or DENN-SV or at least one of its splice variants; and
- (b) monitoring the endogenous levels of IG20 or at least one of its splice variants or DENN-SV or at least one of its splice variants.

[C18] The method of claim 17, wherein the molecule is selected from the group consisting of a chemical regulator, genetic sequence, cDNA, oligonucleotide, protein, peptide or fragments thereof, and antibodies.

[C19] IG20 molecule or its splice variant having an amino acid sequence encoded by nucleic acid sequences represented by GenBank accession numbers AF440100, AF440101, AF440102, AF440103, AF440434.

[C20] IG20 molecule or its splice variant having an amino acid sequence encoded by nucleic acid sequences represented by GenBank accession numbers AY263980, AY263981, AY263982, AY263983, AY263984, AY263985, AY263986, AY263988 and AY263989.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




A**B****C**

FIG. 10






FIG. 11



A



B





FIG. 13

FIG. 13 (continued)

C



D





FIG. 14

A



B





FIG. 15

**Peptide inhibitors**

Caspase-8 FAM-LETD-FMK, Caspase-10 FAM-AEVD-FMK, Caspase-9 FAM-LEHD-FMK

— Untreated
— Treated with TRAIL/
TNF+CHX

FIG. 15 (continued)




FIG. 16




FIG. 17






FIG. 18


A




B



C



D



E





FIG. 19

A



B






FIG. 20 A.



B.



C.

FIG. 20 (continued)





FIG. 21

A



B





FIG. 22
A.



B.





FIG. 23

A.



B.






FIG. 24


A.



B.



C.



D.




FIG. 25

6.





FIG. 26.
A.



B.




FIG. 27




FIG. 28





FIG. 29

Mouse Experiment

Nude Mice
infected with
 1×10^6 PA-1
cells s.c after
11 weeks.



Nude Mice
infected with
 1×10^6

PA-1-IG20
cells s.c after
11 weeks.






FIG. 30




FIG. 31






FIG. 32




FIG. 33




FIG. 34




FIG. 35




FIG. 36




FIG. 37

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/030986

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/17 C07K14/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE, Sequence Search, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>AL-ZOUBI ADEEB M ET AL: "Contrasting effects of IG20 and its splice isoforms, MADD and DENN-SV, on tumor necrosis factor alpha-induced apoptosis and activation of caspase-8 and -3"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 50, 14 December 2001 (2001-12-14), pages 47202-47211, XP002317870</p> <p>ISSN: 0021-9258</p> <p>Discussion abstract</p> <p>-----</p> <p>-/--</p>	1-20



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

16 February 2005

Date of mailing of the international search report

07/03/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Griesinger, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/030986

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EFIMOVA ELENA V ET AL: "Differential effects of IG20 and its splice isoform, DENN-SV, on cell proliferation and apoptosis" FASEB JOURNAL, vol. 16, no. 5, 22 March 2002 (2002-03-22), page A1083, XP009044048 & ANNUAL MEETING OF PROFESSIONAL RESEARCH SCIENTISTS ON EXPERIMENTAL BIOLOGY; NEW ORLEANS, LOUISIANA, USA; APRIL 20-24, 2002 ISSN: 0892-6638 abstract	1-20
X	----- SCHIEVELLA ANDREA R ET AL: "MADD, a novel death domain protein that interacts with the type 1 tumor necrosis factor receptor and activates mitogen-activated protein kinase" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 18, 1997, pages 12069-12075, XP002317872 ISSN: 0021-9258 abstract page 12069, right-hand column, paragraph 2	1-20
X	----- ZHANG Y ET AL: "A splicing variant of a death domain protein that is regulated by a mitogen-activated kinase is a substrate for c-Jun N-terminal kinase in the human central nervous system" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, no. 5, 3 March 1998 (1998-03-03), pages 2586-2591, XP002214181 ISSN: 0027-8424 abstract page 2586, right-hand column, paragraph 3	1-20
A	----- HILGER R A ET AL: "THE RAS-RAF-MEK-ERK PATHWAY IN THE TREATMENT OF CANCER" ONKOLOGIE, KARGER, FREIBURG, DE, vol. 25, no. 6, December 2002 (2002-12), pages 511-518, XP009008407 ISSN: 0378-584X abstract ----- -/--	1-20

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/030986

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>EFIMOVA ELENA V ET AL: "IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs." ONCOGENE, vol. 23, no. 5, 5 February 2004 (2004-02-05), pages 1076-1087, XP002317873 ISSN: 0950-9232 abstract</p> <p>-----</p>	1-20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2004/030986

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-18 could be interpreted to be directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-7,14-20 (all claims partially)

IG20 and the use of IG20 or of antibodies, anti-sense or SiRNA molecules thereof to regulate cell death or cell replication.

1.1. claims: 1-20 (all claims partially)

DENN-SV and the use of DENN-SV or of antibodies, anti-sense or SiRNA molecules thereof to regulate cell death or cell replication.

1.2. claims: 1-20 (all claims partially)

Splice variant of IG20 different to DENN-SV and the use of said splice variant or of antibodies, anti-sense or SiRNA molecules thereof to regulate cell death or cell replication (if more than one further splice variant is claimed, each of said further splice variants is considered to be a further subinvention.
